Study of the cytotoxicity of raw materials of cosmetic and topical pharmaceutical formulations by Verónica Patrícia Moreira da Rocha
 
 
Study of the cytotoxicity 
of raw materials of 
cosmetic and topical 
pharmaceutical 
formulations  
 
Verónica Patrícia Moreira da Rocha 
Mestrado em Bioquímica 
Departamento de Química e Bioquímica 
2015 
 
 
Orientadora 
Isabel Almeida, Professora assistente, FFUP 
Co-orientadora 
Cláudia Marques, Doutorada, FFUP 
 
 
 
 
 
 
Todas  as  correções  
determinadas pelo júri, e só 
essas, foram efetuadas. 
 
O Presidente do Júri, 
 
 
Porto,  
______/______/_________ 
 
FCUP/ICBAS 
Study of the cytotoxicity of raw materials of cosmetic and topical pharmaceutical formulations  
III 
 
 
 
ACKNOWLEDGEMENTS 
 
Com a finalização de mais uma etapa não posso deixar de agradecer a algumas 
pessoas que me apoiaram incondicionalmente. 
Agradeço à minha orientadora Professora Doutora Isabel Filipa Almeida pela sua 
constante dedicação, compreensão, supervisão, sabedoria, disponibilidade, paciência 
e apoio prestado ao longo deste trabalho e à minha co-orientadora Doutora Cláudia 
Marques pela partilha dos seus vastos conhecimentos, paciência, empenhamento e 
disponibilidade que sempre evidenciou ao longo de todo o processo. Agradeço a 
ambas a revisão da dissertação. 
Agradeço a todos os Professores e técnicos do laboratório de Tecnologia 
Farmacêutica da Faculdade de Farmácia da Universidade do Porto por me acolherem 
da melhor forma. Um obrigado especial ao Professor Doutor Paulo Costa pelos 
conhecimentos científicos que me facultou e pela constante disponibilidade 
demonstrada e ao Professor Doutor Domingos Ferreira agradeço pela sua boa 
disposição e motivação. 
À Professora Doutora Emília Sousa e à Professora Doutora Marta Correia-da-Silva 
agradeço a cedência dos compostos obtidos por síntese química. À Doutora Sara 
Cravo agradeço toda a ajuda prestada no evaporador rotativo. 
Um muito obrigada às meninas do laboratório: Ana Cláudia, Ana Rita, Bárbara, 
Gabriela, Isabel, Joana, Karoll, Mariana, Marlene, Rachel, Rita e Sara por todos os 
momentos de boa disposição e inter-ajuda. Um obrigado especial à Marlene pela 
valiosa ajuda nos testes estatísticos e à Isabel por toda a ajuda e força que me deu 
nesta difícil etapa final. 
Pela amizade incondicional, apoio, carinho, por compreenderem as minhas 
ausências e por me ajudarem a passar à frente em alguns momentos maus e por 
festejarem comigo nos momentos bons, agradeço a todos os meus grandes Amigos, 
não citando nomes porque são muitos, mas sabem quem são e são especiais. 
Aos meus pais, avó, irmão, cunhada e sobrinha quero agradecer pelo amor 
incondicional, carinho e força que me dão todos os dias. Agradeço ao meu irmão por 
ser um exemplo para mim e mostrar-me sempre que desistir não é opção. 
 
O meu muito obrigada a todos que, direta ou indiretamente, me apoiaram ou 
prestaram colaboração nesta aventura enriquecedora tanto ao nível científico como 
pessoal. 
IV FCUP/ICBAS 
Study of the cytotoxicity of raw materials of cosmetic and topical pharmaceutical formulations  
 
ABSTRACT 
 
The assessment of the toxicological profile of the raw materials of cosmetics and 
pharmaceutical formulations is a regulatory requirement. This evaluation should take 
into account the route of administration. Considering the specific case of topical 
administration, the preliminary toxicological evaluation of new ingredients can be 
conducted in skin cell lines, in particular keratinocytes and fibroblasts. The objective of 
this work was to study the cytotoxicity of ingredients with potential interest for skin 
application in human keratinocytes (HaCaT cell line). The tested compounds included 
novel substances obtained by chemical synthesis: 1,2-Dihydroxyxanthone (1,2-DHX), 
ascorbic acid persulfated (ASS), chlorogenic acid persulfated (ACS) and resveratrol 
glicoside sulfate (RGS) synthesized in Pharmaceutical Chemistry Laboratory, FFUP. 
Resveratrol (RSV), resveratrol glicoside (RSV-Gli) and a Castanea sativa leaf extract 
were also tested. The study also included nano and micro particles containing RSV. In 
an initial step solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) 
were prepared using a homogenization/sonication technique, and polymeric 
microparticles produced with a piezoelectric atomizing method. The particles were 
characterized in relation to size using a laser diffraction technique. To obtain the C. 
sativa extract, dry leaves were extracted with a solution of ethanol:water (7:3). The final 
dry extract was obtained by lyophilization. Cytotoxicity assays were conducted with an 
immortalized cell line of human keratinocytes (HaCaT). For further characterization of 
cytotoxicity, different tests were selected, namely:  MTT and AlamarBlue® reduction 
assays (assessment of metabolic activity), neutral red (NR) uptake (evaluation of 
lysosomal integrity), exclusion of propidium iodide (PI) and trypan blue (assessment of 
membrane integrity). The results showed that RSV and its derivatives may be 
considered non toxic in future studies for concentrations up to 100 μM for RSV, 500 μM 
RSV-Gli and 1000 μM to RGS. The botanical extract and 1,2-DHX can be safely used 
up to 100 μg/mL and 50 μM, respectively. The lipid nanoparticles prepared and tested 
in this work were not considered as promising topical ingredients. Polymeric particles 
showed deposition on the surface of the cell monolayer and aggregation which led to a 
great variability of the results. The particles present several challenges for toxicological 
testing. Other toxicological tests should be performed in order to meet regulatory 
requirements before considering the use of the compounds tested for cosmetic or 
pharmaceutical products. 
 
Keywords: raw materials, keratinocytes, nanomaterials, cytotoxicity assays  
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RESUMO 
 
A avaliação do perfil toxicológico das matérias-primas dos produtos cosméticos e 
das formas farmacêuticas é uma exigência regulamentar. Esta avaliação deve ter em  
perspetiva a via de administração. No caso particular da administração cutânea, uma 
preliminar avaliação toxicológica de novos ingredientes deve ser conduzida em linhas 
celulares cutâneas nomeadamente, queratinócitos e fibroblastos. O objetivo deste 
trabalho foi o estudo da citotoxicidade de ingredientes com potencial interesse para 
aplicação na pele em queratinócitos humanos (linha celular HaCaT). Os compostos 
testados incluíram substâncias inovadoras obtidas por síntese química: 1,2-di-
hidroxixantona (1,2-DHX), ácido ascórbico sulfatado (AAS), ácido clorogénico 
sulfatado (ACS) e o resveratrol glicosilado sulfatado (RGS), sintetizados no laboratório 
de Química Farmacêutica, FFUP. Resveratrol (RSV), resveratrol glicosilado (RSV-Gli) 
e um extrato de folhas de Castanea sativa também foram estudados. O estudo incluiu 
também nano e micro partículas contendo RSV. Numa etapa inicial foram preparadas 
nanopartículas lipídicas sólidas (SLN) e transportadores lipídicos nanoestruturados 
(NLC) recorrendo a uma técnica de homogeneização/sonicação, e micropartículas 
poliméricas produzidas com um método de atomização piezoelétrica. As partículas 
foram caraterizadas relativamente ao tamanho utilizando uma técnica de difração a 
laser. Para obtenção do extrato de C. sativa, as folhas secas foram extraídas com uma 
solução de etanol:água (7:3). O extrato final seco foi obtido por liofilização. Os ensaios 
de citotoxicidade foram realizados com uma linha celular imortalizada de 
queratinócitos humanos (HaCaT). Para uma caracterização mais aprofundada da 
citotoxicidade foram selecionados diferentes ensaios, nomeadamente: ensaio de 
redução do MTT e do AlamarBlue® (avaliação da atividade metabólica), incorporação 
do vermelho neutro (avaliação da integridade lisossomal), exclusão do iodeto de 
propídeo (PI) e do azul de tripano (avaliação da integridade da membrana plasmática). 
Os resultados mostraram que o RSV e os seus derivados, podem ser considerados 
não tóxicos para estudos futuros em concentrações até 100 μM para o RSV, 500 μM 
para o RSV-Gli e 1000 μM para o RGS. O extrato botânico e a 1,2-DHX podem ser 
considerados seguros até 100 μg/mL e 50 μM, respetivamente. As nanopartículas 
lípidas preparadas e avaliadas neste trabalho não mostraram ser um ingrediente 
promissor para aplicação tópica. As partículas poliméricas depositaram e agregaram 
sobre a superfície da monocamada de células, o que conduziu a uma grande 
variabilidade dos resultados. As partículas apresentam vários desafios para testes 
toxicológicos. Outros testes toxicológicos devem ser realizados de forma a cumprir os 
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requesitos regulamentares antes de considerar a utilização dos compostos testados 
em produtos cosméticos ou farmacêuticos. 
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1. INTRODUCTION 
 
1.1  Safety assessment of raw materials for cosmetic and 
topical pharmaceutical formulations 
 
Millions of consumers use cosmetic and pharmaceutical products on a daily basis. 
The raw materials of cosmetics or pharmaceutical products may be of plant, mineral or 
animal source or obtained by chemical synthesis. The determination of their safety 
profile is of great importance not only for new ingredients but also when a well-known 
and generally recognized as safe ingredient is used in a higher concentration or with a 
different application [1]. Regulatory requirements diverge between cosmetics and 
pharmaceutical products. 
 
The term cosmetic has a broad definition, according to the Cosmetics Regulation, 
cosmetic product “means any substance or mixture intended to be placed in contact 
with the external parts of the human body (…) or with the teeth and the mucous 
membranes of the oral cavity with a view exclusively or mainly to cleaning them, 
perfuming them, changing their appearance, protecting them, keeping them in good 
condition or correcting body odours” and includes skin care products, hair care 
products, nail and lip care products, and sunscreens [2].  
European Regulations regarding the safety of cosmetics were introduced in 1976 
[3] by the European Union’s (EU) Cosmetic Directive which has been periodically 
updated. In 2009, the legislative recast transforms the Cosmetic Directive 76/768/EEC 
into a Regulation. According to the Cosmetics Regulation (EC) No 1223/2009, which 
became fully applicable from 11 July 2013, “a cosmetic product made available on the 
market shall be safe for human health when used under normal or reasonably 
foreseeable conditions of use”. The most significant changes introduced by the new 
Cosmetics Regulation include: strengthened safety requirements for cosmetic 
products (safety report), introduction of the notion of “responsible person”, centralized 
notification of all cosmetic products placed on the EU market, introduction of reporting 
of serious undesirable effects and new rules for the use of nanomaterials in cosmetic 
products [4].  
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Cosmetics do not require a pre-marketing approval, being the safety of cosmetics 
and their ingredients the responsibility of the “responsible person” who must ensure 
that they undergo an expert scientific safety assessment before they are sold. Each 
cosmetic product is considered as an individual combination of cosmetic substances. It 
is generally accepted that the safety evaluation can be done by ascertaining the toxicity 
of its substances [5]. The safety of substances that cause some concern with respect 
to human health, are evaluated at the Commission level by a scientific committee, 
presently called the Scientific Committee on Consumer Safety (SCCS). The SCCS 
evaluates the safety of ingredients such as colorants, preservatives, and UV filters [6]. 
The cosmetic product safety report should contain the toxicological profile of the 
substances included in the cosmetic product for all relevant toxicological endpoints, a 
particular focus on local toxicity evaluation (skin and eye irritation), skin sensitization, 
and in the case of UV absorption photo-induced toxicity shall be made [2]. It is 
noteworthy, the ban on animal testing for cosmetic purposes promoted the 
development of alternative in vitro methodologies for safety evaluation. 
 
Pharmaceutical products, also known as medicines, are a fundamental component 
of both modern and traditional medicine and are defined as any substance or 
combination of substances presented as having properties for treating or preventing 
disease in human beings [7]. Unlike cosmetics a marketing authorization for medicinal 
products has to be issued by the competent authorities. 
The medicine consists of active pharmaceutical ingredients (API) and excipients. 
An API is defined by the International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidance as 
any substance or mixture of substances intended to be used in the manufacture of a 
drug product and that, when used in the production of a drug, becomes an active 
ingredient in the drug product. Such substances are intended to exert a 
pharmacological activity or other direct effect in the diagnosis, cure, mitigation, 
treatment or prevention of disease or to affect the structure and function of the body [8]. 
In turn, excipients are any constituent of a medicinal product other than the active 
substance and the packaging material. The excipients may have several functions, for 
example in the manufacturing process (e.g., glidants, lubricants and binders), the 
release of the drug from the dosage form (e.g., disintegrants) or simply to improve 
handling and dosing uniformity (e.g., fillers or diluents), to provide drug stability (e.g., 
antioxidants), good taste (e.g., sweetening agents and flavours), or appearance (e.g., 
colorant and coating components) [9]. 
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Pharmaceutical products are formulated with a fairly limited number of substances 
in comparison with cosmetics. The raw materials used in the manufacture of a 
medicine have to meet a series of requirements whether they are active substances or 
excipients (Figure 1). Pharmacopeias contain monographs that describe both the 
individual and general quality standards for ingredients, dosage forms and methods of 
analysis for medicines [10].  
 
 
Figure 1: Main requirements for pharmaceutical formulations. Adapted from [11]. 
 
With regard to safety assessment, the development of a pharmaceutical is a 
stepwise process involving an evaluation of both non-clinical and human safety 
information. Human clinical trials are conducted to demonstrate both the efficacy and 
safety of a pharmaceutical, starting with a relatively low exposure in a small number of 
subjects. Clinical trials in which exposure usually increases by dose, duration, and/or 
size of the exposed patient population are also performed [12]. Regarding non-clinical 
safety evaluation both animal models as well as ex vivo and in vitro preparations can 
be used as test systems [13]. 
For excipients, if a precedence of use can be shown in applications where there is 
human exposure, the safety of the material might already be appropriate for potential 
application as an excipient in the pharmaceutical industry. If there is no precedence of 
use in a drug product, then the material is to be considered a new excipient and there 
are a number of conditions set out by the regulatory authorities to allow for its use, 
including safety assessment [14].  
 
The scientific guidelines available for the non-clinical safety evaluation of raw 
materials for medicines and cosmetics are presented on Table 1.  
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Table 1: Scientific guidelines applied to cosmetic and pharmaceutical formulations regarding non-clinical safety 
assessment 
 
Medicines Cosmetics 
Guideline on non-clinical local tolerance 
testing of medicinal products (European 
Medicines Agency, 2014) 
The SCCS’s notes of guidance for testing of 
cosmetic ingredients and their safety 
evaluation 9
th 
revision (European 
Commission, 2015) 
Guidance on nonclinical safety studies for the 
conduct of human clinical trials and marketing 
authorization for pharmaceuticals (M3(R2)) 
(ICH, 2009) 
Cosmetics Europe: guidelines for the safety 
assessment of a cosmetic product 
(Cosmetics Europe, 2004) 
Guideline on repeated dose toxicity (European 
Medicines Agency, 2010) 
Guidance on the safety assessment of 
nanomaterials in cosmetics (European 
Commission, 2012) 
Testing for carcinogenicity of pharmaceuticals 
(S1B) (ICH, 1997) 
Photosafety evaluation of pharmaceuticals 
(S10) (ICH, 2013) 
Guidance on genotoxicity testing and data 
interpretation for pharmaceuticals intended for 
human use (S2(R1)) (ICH, 2011) 
Detection of toxicity to reproduction for 
medicinal products & toxicity to male fertility 
(S5(R2) (ICH, 2000) 
Non-clinical guideline on drug-induced 
hepatotoxicity (European Medicines Agency, 
2008) 
Note for guidance on safety pharmacology 
studies for human pharmaceuticals (European 
Medicines Agency, 2006) 
Guidance for industry: nonclinical studies for 
the safety evaluation of pharmaceutical 
excipients (Food and Drug Administration, 
2005) 
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1.1.1 Toxicological testing of raw materials for topical 
formulations 
 
Procedures for the skin testing of new chemicals and finished products have been 
evolving in the face of technological advancements and political pressure. The 
evaluation of the skin irritation potential is such an example. It was usually performed 
with the method of John Draize [15]. This method consisted in the application under 
occlusion of test compounds on rabbit skin and subsequent evaluation of irritant effects 
[16]. Recently, measures such as prohibition of execution of cosmetics animal testing 
led to the development and validation of alternative in vitro methods using 
reconstructed human epidermis. Currently, several  in vitro skin irritation tests are 
officially validated, namely EpiSkinTM, Modified EpidermTM Skin Irritation Test and 
SkinEthicTM Reconstructed Human Epidermis [5]. These models use normal human 
keratinocytes that, during culturing, form a multi-layered epidermis including a stratum 
corneum at the top, functioning as a barrier [17]. 
Nanomaterials (NMs) are a particular case of cosmetic ingredients. 
Nanotechnologies are a booming business and include the development and 
production of nanosized engineered particles, fibers, coatings, etc., collectively referred 
to as NMs [18]. According to Regulation (EC) No 1223/2009 nanomaterial means an 
insoluble or biopersistent and intentionally manufactured material with one or more 
external dimensions, or an internal structure, on the scale from 1 to 100 nm [2]. 
Currently, these nanosystems can be found in many cosmetic products such as 
sunscreens, creams, tooth pastes, shampoos and cleansing agents. Additionally, 
nanotechnology has been widely studied for medical and pharmaceutical applications 
[19, 20]. Safety data with special considerations to the properties of a specific 
nanomaterial is required for its risk assessment. A guidance document on the safety 
assessment of nanomaterials in cosmetics was published [21]. 
 
On Table 2 a set of toxicological requirements and their scope of application 
(cosmetics or medicines) are listed. Safety requirements for cosmetic ingredients are 
addressed in the “Notes of Guidance for Testing of Cosmetic Ingredients and their 
Safety Evaluation” [5]. Basic requirements for cosmetic substances present in finished 
cosmetic products include acute toxicity (oral, dermal or inhalation), skin and eye 
irritation, sensitization and mutagenicity data. For inclusion of a substance in one of the 
annexes to Regulation (EC) No 1223/2009, in general, points 1. to 6. are considered 
the minimal base set requirements. However, when considerable oral intake is 
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expected or when the data on dermal/percutaneous absorption indicate a considerable 
penetration of the substances through the skin, points 7., 8. and 9. may become 
necessary, as well as specific additional genotoxicity and/or mutagenicity data. Photo-
induced toxicity data are specifically required when the substance is present in a 
cosmetic product that is expected or intended to being used on sunlight-exposed skin 
[5]. 
  The nonclinical safety study recommendations for the marketing approval of a 
pharmaceutical usually include repeated dose toxicity studies, reproduction toxicity 
studies, genotoxicity studies, local tolerance studies, and for drugs that have special 
cause for concern or are intended for a long duration of use, an assessment of 
carcinogenic potential. Other nonclinical studies include pharmacologic studies for 
safety assessment (safety pharmacology) and pharmacokinetic (absorption, 
distribution, metabolism, and excretion-ADME) studies. The complete evaluation of 
dermal tolerance for  pharmaceutical products intended for administration to the skin 
requires a repeated dose dermal tolerance test, and evaluation of the sensitizing 
potential, a photosafety evaluation should also be undertaken [13]. As a general rule, 
the formulation that is intended to be used clinically should be used in all tests. 
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Table 2: General toxicological requirements for cosmetic ingredients or active substances of topical medicines 
 
C refers to Cosmetics and M to Medicines 
 
General toxicological requirements Definition 
1.Acute toxicity (if available) 
C 
 
Adverse effects on health which may result from a 
single exposure to a substance via the oral, 
dermal or inhalation route.  
2.Corrosivity and Irritation (skin and eye) 
C 
 
Corrosion is the potential of a substance to cause 
irreversible damage while Irritation causes 
reversible damage. 
3.Skin sensitization  
C,M 
An agent that is able to cause an allergic 
response in susceptible individuals. 
4.Dermal/percutaneous absorption  
C 
Passage of compounds across the skin, including 
penetration, permeation and resorption. 
 
5.Repeated dose toxicity  
C,M 
Occurs as a result of repeated daily dosing with, 
or exposure to, a substance for a specific part of 
the expected lifespan of the test species. 
 
 
6.Mutagenicity/genotoxicity  
C,M 
 
Mutagenicity refers to the induction of permanent 
transmissible changes in the amount or structure 
of the genetic material of cells or organisms and 
genotoxicity is a broader term and refers to 
processes which alter the structure, information 
content or segregation of DNA. 
 
7.Carcinogenicity  
C,M 
 
Substances are defined as carcinogenic if they 
induce tumors or increase their incidence, 
malignancy or shorten the time of tumor 
occurrence. 
8.Reproductive toxicity  
C,M 
Adverse effects induced by a substance on any 
aspect of mammalian reproduction. 
 
9.Toxicokinetics  
C,M 
Describes the time-dependent fate of a substance 
within the body and includes absorption, 
distribution, biotransformation and/or excretion. 
 
10.Photo-induced toxicity  
C,M 
Occurs as a result of the exposure of the 
substance to a non-cytotoxic dose of UV/visible 
light. 
 
 
11.Safety pharmacology  
M 
The core battery of safety pharmacology studies 
includes the assessment of effects on 
cardiovascular, central nervous, and respiratory 
systems, and should generally be conducted 
before human exposure. 
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Dermal tolerance is an important requirement for topical formulations. Animal 
models or in vitro tests using reconstructed human epidermis have been used for non-
clinical dermal tolerance assessment of raw materials for the cosmetic and 
pharmaceutical industry [13]. Simple cytotoxicity tests can be of value early in the 
discovery process of new drugs or active substances for the pharmaceutical industry. 
These assays can be added to the battery of information (pharmacologic efficacy, 
selectivity, and ADME properties) that is used to differentiate between chemical series 
or aid in compound selection for safety tolerance assessment of drugs in animal 
studies [22].  
Numerous in vitro screening assays have been developed to measure specific 
biological activities of chemicals in specific organs or cell types with an eye to 
elucidating mechanisms of action. For the purposes of hazard assessment, biological 
activity in an in vitro system can identify a mechanism of action or response that could 
be extrapolated to an in vivo end point [23].  
In the following section an approach to in vitro cytotoxicity assays is done. 
 
1.2  In vitro cytotoxicity assays 
 
The detection of cytotoxicity is crucial in many biological fields, e.g. in toxicology 
and in pharmaceutical and cosmetic fields for the assessment of toxic effects elicited 
by chemicals, drugs or cosmetic ingredients, respectively, before they are release for 
use by the public.  
A variety of assays have been developed and used for the measurement of cell 
viability or toxicity and the in vitro proliferation. It is important to make a distinction 
between cytotoxicity or cell viability and proliferation. Cell proliferation is the 
measurement of the number of cells that are dividing in a culture. One way of 
measuring this parameter is by performing clonogenic assays, a defined number of 
cells are plated onto the appropriate matrix and the number of colonies that are formed 
after a period of growth are enumerated or measurement of DNA synthesis as a 
marker for proliferation (e.g., 3 [3H]-thymidine or 5-bromo-2’-deoxyuridine) [24]. 
Definitions of cytotoxicity or cell viability vary depending on the nature of the study. 
Cytotoxicity is the cell-killing property of a chemical (e.g., cosmetic or pharmaceutical) 
or a mediator cell (e.g., cytotoxic T cell), independent from the mechanisms of death, 
while cell viability can be taken as the number of live cells [24]. 
The need for reliable, easy to handle and fast cytotoxicity tests led to the 
development of several assays which are now routinely used and available to detect 
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cytotoxic effects in in vitro cellular systems [25]. These assays have been devised to 
examine and measure cessation of a broad variety of parameters associated with 
biochemical events necessary for sustaining viability and/or evidence of changes in 
membrane integrity leading to cellular disintegration [26]. 
To choose an appropriate in vitro cytotoxicity assay, different parameters as: the 
cell type, culture conditions applied, test compounds, detection mechanism, specificity, 
and sensitivity have to be considered. Cell-toxicity may be assessed by morphological 
changes or by alterations in membrane permeability and/or physiological state inferred 
from the exclusion of certain dyes or the uptake and retention of others [26, 27].  
In the following topic, a brief description, as well as, the advantages and 
disadvantages of the most used cytotoxicity assays will be described. 
 
1.2.1 Evaluation of cell membrane permeability 
 
Widely used standard methods for measuring cell membrane permeability are 
based on the uptake or exclusion of molecules with particular light-absorbing or 
fluorescent properties. An example is the uptake of dyes such as Trypan Blue, Neutral 
Red and Propidium iodide, or the release of cytoplasmic enzyme or of artificial label 
(Figure 2). This evaluation is based on the fact that viable cells have an intact plasma 
membrane while dead cells have a damaged plasma membrane [24].  
 
 
 
 
 
 
 
 
 
Figure 2: Schematic illustration of the three basic principles to assess cell membrane integrity. Adapted from [24]. 
 
10 FCUP/ICBAS 
Study of the cytotoxicity of raw materials of cosmetic and topical pharmaceutical formulations  
 
The advantages of such permeability assays are that they are performed easily and 
with use of multi-wells plates, many dilutions and/or many compounds can be tested 
rapidly [28]. On the other hand, a serious disadvantage of these assays is that the 
initial sites of damage of many cytotoxic agents are intracellular. Consequently, cells 
may be irreversibly damaged and committed to die and the plasma membrane is still 
intact. Thus, these assays tend to underestimate cellular damage when compared to 
other methods. Despite this fact, some permeability assays have been widely accepted 
for the measurement of cytotoxicity [24]. 
 
1.2.1.1  Calcein-Acetoxymethyl assay 
  
The Calcein-acetoxymethyl (AM) assay was developed by Lichtenfels et al. [29]. 
Calcein-AM is a dye that passively crosses the cell membrane and is frequently used to 
stain viable cells [30]. Inside the cells it is converted by intracellular esterases into a 
polar lipid-insoluble fluorescent product, calcein, that is retained by cells with intact 
membranes but that is released by damaged ones, producing an intense green signal 
(Figure 3). 
 
Figure 3: Mechanism of conversion of Calcein-AM to Calcein by esterases. Adapted from [31]. 
 
Release of calcein by damaged cells in the supernatants can be measured rapidly 
and with a high level of sensitivity by a fluorimeter or flow cytometry [32].  
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1.2.1.2 Fluorescein Diacetate uptake assay 
 
Another assay for evaluation of cell membrane permeability involves the uptake of 
the fluorescein diacetate (FDA), one dye permeable to the cell membrane. The assay 
is based on the hydrolysis of the dye, FDA, by esterases in cells with intact plasma 
membranes [33].  
A non-polar substrate and non-fluorescent, FDA, is incorporated into live cells and 
is converted into polar and green fluorescent product, fluorescein, by cellular hydrolysis 
(Figure 4). Under the appropriate excitation and emission wavelengths, viable cells 
fluoresce as green and this feature can be measured either by visual counting with a 
fluorescence microscope or by flow cytometry [34]. 
 
 
Figure 4: Mechanism of conversion of FDA to Fluorecein by esterases. Adapted from [35]. 
 
One advantage of using FDA is the speed at which results can be obtained, as the 
previous method. The disadvantages that can arise when using this test are the false 
negatives, when FDA is converted to fluorescein in the absence of live cells or 
otherwise when the fluorescein that is produced by live cells may not be detectable if 
its fluorescence is quenched [36].  
 
1.2.1.3 Lactate Dehydrogenase leakage assay 
 
Lactate dehydrogenase (LDH) is a soluble cytosolic enzyme which serves as an 
indicator of lytic cell death since it is readily released into extracellular medium 
following cellular membrane damage resulting from apoptosis or necrosis [37]. There 
are other cellular enzymes, such as adenylate kinase and glucose-6-phosphate 
dehydrogenase that are used as cell death markers. However, these are not stable and 
only LDH does not lose its activity during cell death assays. Therefore, cytotoxicity 
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assays based on LDH activity are more reliable than other enzyme-based cell death 
assays [24].  
The LDH leakage assay is based on the conversion of lactate to pyruvate in the 
presence of LDH with parallel reduction of NAD, by the following reaction: 
 
 
                                  
 
The formation of NADH from the above reaction leads to a change in absorbance at 
340 nm. LDH is rapidly released into the cell culture supernatant upon damage of the 
cell membrane, an indicator of irreversible cell death [38, 39].  
Reliability, speed and simple evaluation are some of characteristics of this assay 
[40]. Although widely accepted as a marker of cell death, it should be noted that this 
test is simply an index of cell membrane integrity, and in certain circumstances can be 
positive even when the cell count is not significantly modified [37]. 
 
1.2.1.4 Neutral Red uptake assay 
 
The neutral red (3-amino-m-dimethylamino-2-methlphenazine hydrochloride) is a 
weak cationic dye that has been used previously for the identification of the viable cells 
in cultures [41]. 
The neutral red (NR) assay is based on the initial protocol described by 
Borenfreund and Puerner [42]. This assay focuses on the uptake and subsequent 
lysosomal accumulation of the supravital dye NR. Cellular uptake of the dye is 
accomplished by passive transport across the plasma membrane. Accumulation of NR 
within lysosomes occurs either from the binding of NR to fixed acidic charges, such as 
those of polysaccharides, within the lysosomal matrix, or from the trapping of the 
protonated form of NR within the acid milieu of the lysosomes [43].  
In damaged or dead cells NR is no longer retained in the cytoplasmic vacuoles and 
the plasma membrane does not act as a barrier to retain the NR within the cells. It 
quantifies the number of viable, uninjured cells after their exposure with test agents [39, 
44]. 
This assay does not measure the total number of cells, but it does show a reduction 
in the absorbance related to loss of viable cells [43]. 
 
LDH 
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1.2.1.5 Propidium Iodide exclusion assay 
 
Propidium iodide (PI) is a fluorescent molecule that can only penetrate cell 
membrane of dying or dead cells and thus identifies dead cells within a population. 
Upon entering dead cells, PI binds to double-stranded DNA by intercalating between 
base pairs. As this intercalation is mediated by non-covalent forces, these dyes must 
remain present in the buffer used to resuspend cells for data acquisition so that dead 
cells will remain labeled [45]. The uptake of PI by the cells results in orange 
fluorescence that can be assessed by fluorescence and flow cytometry [46]. 
 
1.2.1.6 GF-ACF assay 
 
This assay utilizes the cell-permeant protease substrate glycylphenylalanyl-
aminofluorocoumerin (GF-AFC) that penetrates live cells where cytoplasmic 
aminopeptidase activity removes the gly and phe aminoacids to release 
aminofluorocoumarin (AFC) and generate a fluorescent signal proportional to the 
number of viable cells (Figure 5) [47, 48].  
 
 
Figure 5: Mechanism of conversion of GF-AFC to AFC by cytoplasmic aminopeptidase activity. Adapted from [47]. 
 
The selective detection of viable cells by this method is possible because the 
proteolytic activity towards the GF-AFC substrate is dependent upon the continued 
maintenance of membrane integrity. Viability can be measured using a fluorometer. 
The proteolytic activity decays within seconds after a cytotoxic event, so non-viable 
cells do not contribute appreciably to fluorescence generation [48]. 
One of the advantages of the GF-AFC substrate is that it is relatively non-toxic to 
cells in culture. 
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1.2.1.7 Trypan Blue exclusion assay 
 
One of the earliest methods for assessing cytotoxicity was trypan blue exclusion 
assay, which is still widely used today.  
The trypan blue is a vital stain used to stain dead cells or tissues. When membrane 
integrity of the cells is compromised, there is an uptake of the dye into the cells so that 
viable cells, which are unstained, appear clear with a refractile ring around them and 
nonviable cells appear dark blue colored [25, 28]. This traditional method involves 
manual staining and use of a hemocytometer for counting. Recent advances in 
instrumentation have led to a number of semi- or fully automated systems that can 
increase the throughput and accuracy of this technique [49]. 
This method is simple, quick, inexpensive, and requires only a small fraction of total 
cells from a cell population. However, trypan blue staining cannot be used to 
distinguish between the healthy cells and the cells that are alive but with impaired cell 
functions. 
 
1.2.2 Evaluation of metabolic activity 
 
One parameter used as the basis for cytotoxicity assays is the evaluation of 
metabolic activity of the viable cells including assays based on tetrazolium and 
resazurin reduction [26]. The metabolic assay do not provide direct information about 
total cell numbers, but measure the viability of a cell population relative to control. One 
potential disadvantage of these metabolic assays is that there is no differentiation 
between cells that are actively dividing and those that are quiescent which may result 
in an over-estimation of cell number [27]. 
 
1.2.2.1 AlamarBlue® reduction assay 
 
AlamarBlue® is an important and sensitive oxidation-reduction indicator that is used 
to evaluate metabolic function and cellular health. The resazurin (oxidized form) is a 
blue weakly fluorescent indicator dye that changes into highly fluorescent pink resorufin 
(reduction form) in response to irreversible chemical reduction (Figure 6) [50]. 
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Figure 6: Mechanism of reduction of resazurin to resorufin [50]. 
 
Inside the cell, AlamarBlue® undergoes enzymatic reduction in mitochondria due to 
the activity of enzymes such as flavin mononucleotide dehydrogenase, flavin adenine 
dinucleotide dehydrogenase, nicotinamide adenine dehydrogenase, and cytochrome 
[51]. It was also noted that cytosolic and microsomal enzymes have abilities to reduce 
resazurin [52]. The pink resorufin is secreted outside the cells to the medium which 
results in visible colour change from blue to pink. The rate of reduction based on colour 
change can be quantified colorimetrically or fluorometrically and reflects the number of 
viable cells [50].  
AlamarBlue® is considered as very sensitive technique, non-toxic to cell cultures 
and is less likely to affect normal metabolism by not interfering with the electron chain 
[50, 53]. 
 
1.2.2.2 Tetrazolium Salts reduction assay 
 
A variety of tetrazolium compounds have been used to detect viable cells. The most 
frequently used tetrazolium salt is 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) [27]. 
The MTT reduction assay was the first homogeneous cell viability assay developed 
for a 96-well format that was suitable for high throughput screening (HTS) [54]. This 
assay is used to determine the level of metabolic activity in eukaryotic cells. It is based 
on the conversion of soluble tetrazolium into insoluble formazan crystals reduction 
(Figure 7) by cellular mitochondrial and cytosolic enzymes of actively growing cells [25, 
26]. The formazan product is impermeable to the cell membranes and requires 
solubilization of product. 
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Figure 7: Structures of MTT and colored formazan product [47]. 
 
Problems surrounding MTT insoluble formazan product prompted investigation and 
the creation of alternative tetrazoliums with different properties, namely to generate 
formazan products that are directly soluble in cell culture medium [26]. Tetrazolium 
compounds which fit this category include 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS), sodium 3′-[1-
phenylamino)-carbonyl]-3,4-tetrazolium]-bis(4-methoxy-6-nitrobenzene) sulfonic acid 
hydrate (XTT) and 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene 
disulfonate (WST-1) [55, 56]. These derivatives are reportedly more sensitive and have 
fewer steps as the converted product is released into the medium, meaning no step is 
required to dissolve the insoluble product (a requirement when using MTT). However, 
MTT is very robust and is metabolized by most cell types, whereas some of the newer 
alternatives are not suitable for all cells [24, 25]. 
Thus, selection of the most appropriate tetrazolium salt as an indicator of metabolic 
activity is important. 
 
1.2.3 Evaluation of adenosine triphosphate content 
 
The nucleotide adenosine triphosphate (ATP) that is present in all metabolically 
active cells plays an important role in energy exchange in biological systems. It 
functions as the principal immediate donor of energy. ATP has been used as a tool for 
the functional integrity of living cells, since all cells require ATP to remain alive and 
carry out their specialized function [57, 58]. During the process of cell death, there is a 
loss of ability to synthesize ATP and endogenous cytoplasmic ATPases rapidly remove 
any remaining ATP [26]. 
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Measuring the amount of ATP from samples of cells in culture has been widely 
accepted as a valid marker of the number of viable cells present under most 
experimental conditions [26]. Many methods have been used for evaluation of ATP 
content, but the most successful technique is the bioluminescent assay, because of its 
high sensitivity and wide dynamic range [57]. The disadvantage of this method is the 
luminescence-readout, which could be influenced by quenching side effects in the 
samples [59]. 
 
1.2.3.1 Bioluminescent assay 
 
In the bioluminescent assay, the enzyme, luciferase catalyzes the formation of light 
from ATP and luciferin [44], by the following reaction: 
 
ATP + D-Luciferin + O2 → Oxyluciferin + AMP + PPi + CO2 + Light   (560nm)  
 
Cellular ATP can be measured by direct lysis of the cells with a suitable detergent, 
the released ATP is then free to react with the luciferin-luciferase, leading to light 
emission.  The emitted light intensity is linearly related to the cell ATP concentration  
and can be measured using a luminometer [58]. 
The principal advantages of ATP detection were shown to be its sensitivity and 
reproducibility [60]. The disadvantages of this assay include that it kills the cells and so 
the sample generally cannot be used for other purposes after treatment with the 
reagent.  
 
1.2.4 Evaluation of protein content 
 
The evaluation of protein content is an indirect measurement of cell viability. The 
most used assays are: bicinchoninic acid and sulphorhodamine assays. 
 
1.2.4.1 Bicinchoninic Acid assay 
 
The bicinchoninic acid (BCA) assay also know Smith assay was described by Smith 
[61].  The principle this assay is similar to the formation of a Cu2+-protein complex 
under alkaline conditions, followed by reduction of the Cu2+ to Cu1+ [62].  
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In this assay, the amount of reduction is proportional to the protein present, 
exhibited by a color change of the sample solution from green to purple in proportion to 
protein concentration, which can then be measured using colorimetric techniques or 
absorbance. The major advantage of the BCA is that it is stable under alkali conditions 
[63]. One disadvantage of the BCA assay is that it is susceptible to interference by 
some chemicals present in protein samples, including reducing agents or copper 
chelators [64]. 
 
1.2.4.2 Sulphorhodamine assay 
 
The Sulphorhodamine (SRB) assay is a popular in vitro cytotoxicity assay 
developed by Skehan et. al. [65]. This assay is based on binding of the SRB to basic 
aminoacids of cellular proteins and colorimetric evaluation provides an estimate of total 
protein mass, which is related to cell number [66]. 
The advantages of this test include better linearity, higher sensitivity, a stable end 
point that does not require time-sensitive measurement and lower cost [67].  
 
 
Cytotoxicity assays described herein are just a few of the commonly used assays. 
These can be used as a prediction of the adverse effects of test compounds on living 
systems, for the detection  of toxic thresholds, and expansion of experimental data sets 
to include multiple toxicity end-point analysis, which are required for any robust 
screening regime [27].  
In Table 3, the cytotoxicity assays described in this topic are presented, grouped by 
the parameter evaluated, as well as the principle of detection of each test. 
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Table 3: Summary of the most used in vitro cytotoxicity assays 
 
Evaluated parameter Cytotoxicity assay Detection 
principle 
 
 
 
 
Cell membrane 
permeability 
Calcein-AM Florescence or Flow 
cytometry 
FDA uptake Fluorescence or Flow 
cytometry 
LDH release Absorbance 
NR uptake Absorbance 
PI exclusion Fluorescence or Flow 
cytometry 
GF-AFC Fluorescence 
Trypan Blue exclusion Hemocytometer 
 
 
Metabolic activity 
AlamarBlue® reduction Absorbance or 
Fluorescence 
Tetrazolium salts 
reduction  
    Absorbance 
ATP content Bioluminescent Luminescence 
 
Protein content 
BCA Absorbance 
SBR Absorbance 
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1.3  Use of cytotoxicity assays in safety assessment of 
raw material for cosmetic and topical pharmaceutical 
formulations  
 
The skin is the first site of contact for many compounds, including ingredients of 
cosmetics or dermal pharmaceuticals. Skin, the major human organ, is a 
heterogeneous membrane: lipophilic on its surface and hydrophilic in its deeper layers. 
It forms a remarkable protective barrier against the external environment, helping to 
regulate temperature and fluid balance, keeping out harmful microbes or chemicals and 
offering some protection against sunlight and oxidation [68, 69]. 
Histologically, the skin has three different layers – epidermis, dermis and 
hypodermis (Figure 8) – that have distinct composition and functions. 
 
 
 
 
 
 
 
 
Figure 8: Structure of skin tissue [70]. 
 
 Epidermis 
 
Epidermis is the outermost structure of human skin and is relatively thin depending 
on body part. The palmar and plantar areas of the feet present the thickest epidermis. 
This tissue is a stratified squamous epithelial film and is an avascular layer, being fed 
through the diffusion of nutrients from the dermis. It consists of several layers (listed 
from outermost to innermost layer) namely the stratum corneum, stratum granulosum, 
stratum spinosum, and stratum basalis (Figure 9). In the thickest areas of the skin, 
another layer called stratum lucidum is visible, being located immediately below the 
stratum corneum [71-74]. 
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Figure 9: Structure of the epidermis. Adapted from [75]. 
 
Keratinocytes are the predominant cells in the epidermis and multiply continuously, 
safeguarding the constant renewal of the epidermis. On the process of migration of 
keratinocytes from the stratum basale to the stratum corneum, named keratinization, 
the cells are undergoing changes in form and chemical composition, and become rich 
in keratin. Keratinocyte transit time is about 14 days and turn over time within stratum 
corneum is also around 14 days,  although certain inflammatory conditions can affect 
these turn over times [71]. This way, the cells eventually die forming an outer layer, 
which imparts strength and forms an impervious barrier on the skin. The mature 
keratinocytes are formed by a high amount of soluble, low molecular weight 
substances which effectively bind water to prevent dehydration of the skin. In addition 
to the keratinocytes, the epidermis has other cell types: melanocytes, Langerhans 
cells, and Merkel cells. Melanocytes are branched cells, located between the 
keratinocytes of the basal layer and are responsible for production of melanin, which is 
important for the protection of skin against ultra-violet radiation and free-radicals. 
Langerhans cells are found throughout the epidermis and show defense immune 
functions. Merkel cells are especially found on thick skin areas and at the fingertips, 
and are responsible for cutaneous sensation [73, 76]. 
 
 
 
 
 
 
22 FCUP/ICBAS 
Study of the cytotoxicity of raw materials of cosmetic and topical pharmaceutical formulations  
 
 Dermis 
 
The dermis is a connective tissue layer and contains a collagen- and elastin-
containing extracellular matrix, primarily composed of type I collagen, as well as an 
abundance of blood vessels and specialized nerve endings, thus providing structural 
and nutritional support to the skin [68, 72, 77]. The dermis contains four major resident 
cell types: fibroblasts, dermal dendritic cells, macrophages, and mast cells. Various 
infiltrative inflammatory cells can also be found in the dermis under different conditions 
[72]. 
The dermis has two distinct layers: the reticular dermis and papillary dermis. The 
reticular dermis is the main layer of the dermis and is continuous with the hypodermis 
and has a predominance of elastic and collagen fibers. The papillary dermis is 
composed of papillae extending towards the epidermis. Compared with the first, the 
papillary dermis has fewer fibers and more cells. This layer of skin also contains 
numerous blood vessels, to provide nutrients to the epidermis, removing waste 
products and helps to regulate the body temperature [73]. 
 
 
 Hypodermis 
 
The hypodermis or subcutaneous fat layer is situated beneath the dermis and 
connects this with the underlying organs. It is primarily composed of well-vascularized 
adipose tissue and loose connective tissue, which insulates the body and provides both 
thermoregulatory and mechanical functions [71-73, 78]. 
 
 
The assessment of cytotoxicity in skin cells can be taken as a measure of the skin 
irritation potential. The evaluation of the skin irritation potential is essential to ensuring 
the safety of human in contact with a wide variety of cosmetic and/or pharmaceutical 
substances. 
Traditionally, the assessment of skin irritation involved the use of laboratory animals 
[79, 80]. However, since the Regulation (EC) 1223/2009 has come into force, animal 
testing of cosmetic and ingredients was banned and the study of their safety has 
moved towards in vitro methodologies. Cultured human skin cells are a potentially 
useful model for skin irritation testing. In vitro cultures of the monolayer using primary 
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human keratinocytes, dermal fibroblasts or immortalized epidermal cell lines have been 
used in various in vitro irritation assays [81].  
In vitro cytotoxicity assays have the advantage of being relatively inexpensive, 
standardized, sensitive and allow for rapid screening of compounds [82].  
The most common in vitro cytotoxicity assay is MTT [83]. This assay is used in 
primary human keratinocytes [84, 85], immortalized keratinocytes [86], melanocytes 
[87] and fibroblasts [88]. Reconstructed human epidermal skin models are being used 
increasingly for safety testing of chemicals. These models have the advantage of 
allowing topical application of the compounds, evaluation of formulations and poorly 
soluble compounds, as well as measurement of local toxicological effects in target cells 
[89]. MTT reduction assay also is very used in reconstructed human epidermis [90-93]. 
 
 
1.3.1 Analyzed antioxidants raw materials  
 
The skin has an antioxidant defense system that prevents UV-induced oxidative 
stress. Nevertheless chronic and excessive exposure to UV-radiation leads to oxidative 
stress and oxidative damage [94]. The topical application of antioxidants has achieved 
great expression, owing to their ability to prevent or minimize the UV induced-
deleterious effects of reactive species on the skin [95]. 
In this work were analyzed several compounds: resveratrol and its derivatives; 
resveratrol-loaded lipid and polymeric particles, xanthone and plant extract. 
 
 
 Resveratrol and its derivatives 
 
The Resveratrol - RSV (3, 5, 4’ -trihydroidroxystilbene) a natural antioxidant 
compound is a non flavonoid polyphenol, present in different plants (peanuts, pistachio 
nuts, red grape seeds and skins, red wine, and other plant-derived food products) [96]. 
Several beneficial effects have been attributed to RSV and its use has been proposed 
in the treatment or prevention of different diseases [97].  
The resveratrol glicoside – RSV-Gli (3, 5, 4’ -trihydroidroxystilbene-3-β-D-
glucopyranoside) is an natural precursor of RSV and known for its favorable 
therapeutic properties: cardiovascular effects, neuroprotection, anti-inflammatory and 
immunoregulatory effects, anti-oxidation, anti-tumor, liver and lung protection [98]. 
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The resveratrol glicoside sulfate - RGS (3, 5, 4’ -trihydroidroxystilbene-3-β-D-
glucopyranoside persulfate) was obtained by chemical synthesis and demonstrate in 
vitro anticoagulant and antiplatelet activities [99, 100]. In docking study, RGS binds 
more stably to sirtuin (lower binding free energy) than the RSV. RGS establishes polar 
interactions with 5 sirtuin residues and stacking interactions with the substrate peptide, 
whereas RSV establishes only one polar interaction (unpublished results). These 
results support the interest of this derivative for skin care formulations. 
The chemical structure of RSV and its derivatives (RSV-Gli and RGS) is showed in 
Figure 10. 
 
 
 
Figure 10: Chemical structure of RSV and its derivatives studied in this work. 
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 Lipid and polymeric particles  
 
Due to its low chemical stability, poor solubility, inefficient systemic delivery, and 
low bioavailability [101], RSV was encapsulated in lipid and polymeric particles. 
Lipid nanoparticles can be solid lipid nanoparticle (SLN) or nanostructured lipid 
carriers (NLC) (Figure 11). The first ones, were invented 20 years ago and are 
prepared from a lipid matrix that is solid at body and room temperature and stabilized 
by suitable surfactants [102] and NLC are 2nd generation of solid lipid-based colloidal 
carriers and are composed of a mixture of a solid and a liquid lipid which lipid matrix is 
solid at room and body temperature [103]. 
 
 
Figure 11: Lipid nanoparticles [104]. 
 
The benefits of the lipid nanoparticles include the employment of biocompatible and 
biodegradable materials, which lead to a low or total absence of toxicity and the ability 
to transport lipophilic drugs [104]. 
On the other hand, polymeric particles are solid colloidal particles that are 
dispersed in the liquid and upon water evaporation, they get well organized on the 
dosage form solid surface to form close-packed arrays. Eudragit® RS 30D was the 
utilized polymer. It is the synthetic homopolymer of poly(acrylate) and 
poly(methacrylate) [105]. 
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 Chlorogenic acid persulfate and Ascorbic acid 
persulfate 
 
 
Chlorogenic acid persulfate (ACS) and ascorbic acid persulfate (ASS) (Figure 12) 
are compounds obtained by chemical synthesis with in vitro anticoagulant, antiplatelet 
and antioxidant activities [99, 100]. 
 
 
 
 
 
Figure 12: Chemical structure of ACS and ASS studied in this work. 
 
 
 
 Xanthone 
 
Chemically, xanthones are a class of oxygenated heterocyclic compounds with a 
dibenzo--pyrone scaffold [106]. Xanthones can be considered as “privileged 
structures”, considering that their scaffold contains a rigid ring system allowing the 
insertion of a variety of substituent’s capable of interacting with several biological 
targets. Many xanthones with phenolic groups have been described for their 
antioxidant properties [107]. These properties have been implicated also with their anti-
inflammatory and cancer chemopreventive activities [108]. In the present work, a 1,2-
dihydroxyxanthone (Figure 13) was used.  
 
 
 
Figure 13: Chemical structure of 1,2-dihydroxyxanthone studied in this work. 
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 Castanea sativa leaf extract 
 
Many natural compounds have a wide range of biological activities including 
antioxidant, chemopreventive, anti-inflammatory, neuroprotective, and cardioprotective 
effects [109].  
Castanea sativa (C. sativa) is a species of the flowering plant family Fagaceae, 
mainly cultivated in temperate regions like Asia, North of Africa and Southern Europe. 
Its leaves are used in folk medicine to treat cough, diarrhea and rheumatic conditions, 
lower back pain, and stiff joints or muscles [110].  
As in other medicinal plants, some of the active substances have been identified as 
phenolic compounds. The scavenging ability has been reported in several studies for 
different ROS, such as superoxide radical (O2
•-), hydroxyl radical (HO•), peroxyl radical 
(ROO•), hydrogen peroxide (H2O2) and singlet oxygen (
1O2), which are implicated in 
skin aging [111]. The utilization of hydroalcoholic extracts from C. sativa leaves (which 
contain rutin, ellagic acid, hyperoside, isoquercitrin and chlorogenic acid) in cosmetic 
compositions has been considered safe and suitable for preventing and treating 
photoaging [112]. 
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2.  AIM 
 
The aim of this Master’s dissertation was to study the cytotoxicity of a series of 
ingredients with potential interest for topical application and determine the 
concentration range for each compound that can be used in future assays to confirm 
the potentialities of these raw materials for application on the skin. For this purpose we 
used ingredients of natural origin, ingredients obtained by chemical synthesis and also 
the ingredient loaded in lipid nanoparticles and polymeric microparticles and five 
distinct cytotoxicity assays were employed. 
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3. MATERIALS AND METHODS 
 
3.1 Materials 
 
Cetyl palmitate pellets and Eudragit® RS 30D (Poly(ethyl acrylate-co-methyl 
methacrylate-co-trimethylammonioethyl methacrylate chloride)) were purchased from 
Gattefossée SA (France) and from Evonik (Germany), respectively. Resveratrol (RSV) 
was purchased from Fragon (Brazil). Ethanol (EtOH) and Methanol were supplied by 
Aga (Portugal) and Merck KgaA (Germany), respectively. Polysorbate 60 (Tween® 60), 
Miglyol® 812 (caprylic/capric triglyceride) and glycerin were purchased from Acofarma 
(Spain). Formic acid and Acetic acid glacial were purchased from Panreac química SA 
(Spain). Immortalized human keratinocyte (HaCaT) cell line was obtained from Cell 
Lines Service (CLS) (Germany). Dulbecco’s Modified Eagles’s Medium (DMEM) with 
4,5 g/L D-glucose and pyruvate, Inactivated Fetal Bovine serum (FBS), Penicillin-
Streptomycin solution, Dulbecco’s Phosphate Buffered Saline (DPBS) without calcium 
chloride and magnesium chloride, 0,25% trypsin-EthyleneDiamineTetraacetic Acid 
(EDTA)  solution and TritonTM X-100 were supplied by Gibco® by Life Technologies 
(USA). Dimethyl sulfoxide (DMSO), Trypan Blue 0,4% solution and Neutral Red (NR) 
solution were purchased from Sigma-Aldrich® (USA). AlamarBlue® was provided by 
Thermo ScientificTM (USA). MTT and Propidium iodide were bought to Life 
Technologies (USA). The water used in all experiments was purified water obtained 
using a  Direct-Q® Water Purification System (Merck Millipore, Darmstadt, Germany)  
with a reverse osmosis process. 
 
3.2 Methods 
 
3.2.1 Preparation of the C. sativa leaf extract  
 
For the preparation of the C. sativa leaf extract a method optimized by Almeida 
[113] was utilized. C. sativa leaves were collected during July 2003 in Mirandela and 
dried at room temperature for 3 weeks, to obtain a moisture content of less than 10%. 
Dried leaves (8 g) were grounded (500 µm) and extracted five times (5 x 200 mL) with 
ethanol (EtOH):water (7:3) at 40°C under magnetic stirring (10 min, 500 rpm). Each 
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alcoholic extract was filtered using a glass filter G4 funnel (5–15 μm porosity, Schott, 
Germany), and gathered in a kitasato flask. Ethanol was evaporated at 40°C under 
vacuum with a rotary evaporator (R-114, Büchi, Switzerland). Finally, the resulting 
aqueous mixtures were lyophilized (SP Scientific, Virtis wizard 2.0, USA) for 24 hours, 
generating the final dry extract, which was kept in an amber flask at room temperature 
in a desiccator. The basic steps of this preparation method are described in Figure 14. 
 
 
Figure 14: Overview of basic steps of C. sativa leaf extract preparation. 
 
3.2.1.1 Qualitative analysis of the phenolic composition of 
C. sativa leaf extract   
 
In order to confirm the presence of phenolic compounds of interest, the C. sativa 
EtOH:water (7:3) leaf extract was analysed using High Performance Liquid 
Chromatography (HPLC) (Dionex Corporation, Sunnyvale, USA) by comparing 
retention times of compounds present in the extract with retention times of standards 
previously analysed with the same chromatographic conditions.  
The lyophilized extract was dissolved in EtOH:water (7:3) and filtered (0.22 μm) 
before being analysed. The sample was injected on a C18 Waters Spherisorb® ODS2 
0.46x25x5μm column equipped with a Waters Spherisorb® pre-column (Waters 
Corporation, EUA) at 20°C, with detection at 280 nm, 320 nm and 350 nm. Organic 
phase was methanol and aqueous phase was water/formic acid (19:1 (v/v)). The 
separation was obtained at a flow rate of 0.9 mL/min with a gradient program described 
on Table 4. 
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Table 4: Gradient program used for identification of phenolic compounds of C. sativa EtOH:water (7:3) leaf extract 
 
Time (min) Aqueous 
phase 
Organic 
phase 
0 95 5 
3 85 15 
13 75 25 
25 70 30 
39 55 45 
42 55 45 
44 50 50 
47 45 55 
50 30 70 
56 25 75 
60 20 80 
 
 
3.2.2 Preparation of nano and microparticles 
 
For the preparation of lipid nanoparticles (SLN and NLC) a high shear 
homogenization technique was used based on previous studies performed in our lab 
[104, 114]. The composition of the SLN and NLC produced in this work are described 
on Table 5. 
The lipid phase with the surfactant and the aqueous phase were heated to 70ºC 
(lipid’s melting point) separately. Then, RSV was dissolved in the lipid phase and the 
aqueous phase was added to lipid phase. The emulsion was submitted to a 
homogenization process (Ultra-Turrax T25, IKA®-Labortechnik, Germany) at a stirring 
speed of 13500 rpm for 2 minutes followed by sonication with a Ultrasonic Processor 
(VCX 130, Sonics Vibracell, USA) with intensity of 80% for 2 minutes. Finally, the 
nanoparticles underwent a rapid cooling process with running tap water. Empty SLN 
and empty NLC were prepared in a similar way, without adding RSV. 
The lipid nanoparticles were prepared extemporaneously for all cytotoxicity assays. 
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Table 5: The formulation parameters of empty and RES-loaded SLN/NLC 
 
 SLN empty SLN-RSV NLC empty NLC-RSV 
Cetyl Palmitate 
(solid lipid at room and 
physiological temperature) 
10% 9.9% 7% 6.9% 
Tween 60 
(surfactant) 
2% 2% 2% 2% 
Mygliol 812 
(liquid lipid at room and 
physiological temperature) 
- - 3% 3% 
RSV 
(to be encapsuled) 
- 0.1% - 0.1% 
Milli-Q Water q.s. 100% q.s. 100% q.s. 100% q.s 100% 
 
 
 
For the preparation of polymeric microparticles a piezodriven spray generation 
apparatus (Nano Spray Dryer B-90, Büchi, Switzerland) (Figure 15) was used. 
Polymeric microparticles containing RSV (Poly-RSV) and empty particles (Poly) were 
produced. RSV was dissolved in EtOH:water solution (20:80) until saturation and mixed 
with Eudragit® RS 30D (0.5%). The sample was atomized by piezoelectrically driven 
membrane vibrations in the small spray cap and millions of precisely sized droplets 
were ejected each second by the vibrating actuator. These droplets passed through the 
chamber to form dried solid particles that were electrostatically charged and collected 
at the collecting electrode. The spray drying experiments were executed using the 
following settings: spray cap (hole size): 7 μm; inlet temperature: 120 ºC, compressed 
air flow: 100 mL/min; pressure: 33-35 mbar and spray: 80%. 
 
 
 
Figure 15: Operating diagram of Nano Spray Dryer B-90. Adapted from [115]. 
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3.2.2.1 Particle size measurements 
 
Particle size of nano and microparticles was analyzed by a laser diffractometry 
technique (Mastersizer 3000, Malvern, UK). With this technique the intensity of 
scattered light is measured as a laser beam passes through a dispersed particulate 
sample. The range of this apparatus is from 0.01 to 3500 μm. 
The determination was performed at room temperature using water as a dispersant 
with a refractive index of 1.33. The refractive index and absorption index were 1.1 and 
0.01 for lipid nanoparticles and 1.48 and 0.1 for polymeric microparticles. The sample 
was added to the dispersant until 5-10% of obscuration (preferably 6%) is reached and 
tested five times at 1000 rpm. The Dv10, Dv50, Dv90 and Span parameters were 
obtained by calculating the average of five runs. Only the measurements with residuals 
and weighted residuals near and below 2% were considered.  
 
3.2.3 Cell Culture 
 
The in vitro cytotoxicity was studied using HaCaT cells. The HaCaT adherent and 
monolayer cell line is an immortal non-cancerous human keratinocyte cell line, which 
was devised from skin of a Caucasian male with 62 years old. 
HaCaT cells were maintained at 37°C in a humidified atmosphere of 95% air and 
5% CO2 (Heraeus HeraCell 150 Air-Jacketed CO2 Incubator) in DMEM with 10% FBS 
and 1% antibiotics (10 000 units/mL penicillin and 10 000 µg/mL streptomycin). 
Using an inverted microscope (Motic®, AE2000 Inverted Microscope), cell 
confluence was assessed. When cells reached 70-80% confluence, subculture was 
done to prevent cell death. Initially, the culture medium was aspirated and the cells 
were washed twice with DPBS, then the cells were trypsinized by adding trypsin-EDTA 
and incubated for 5 to 8 minutes at 37°C in a 5% CO2 atmosphere. After cell detaching, 
medium was added in order to block the action of trypsin and cell suspension was 
centrifuged at 416g for 5 minutes. The supernatant was discarded, the pellet 
ressuspended in culture medium and cells were counted. For cell counting: 10 µL of 
cell suspension was added to 90 µL of 0.4% trypan blue vital dye (1:10), ressuspended 
and placed in a Neubauer chamber (Marienfeld Superior, Germany). Using inverted 
microscope viable cells (cells that do not incorporate the dye trypan blue) were then 
counted in a Neubauer chamber. The number of cells in the total volume was 
calculated with the following equation:  
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                       (equation 1) 
 
where, n is the number of viable cells counted and d is the dilution coefficient. 
 
For cell freezing, DMSO (5% v/v) was used a cryo-preservative to prevent the 
formation of crystals during the storage phase.  
 
3.2.3.1 Characterization of the HaCaT cell line 
 
One of the key parameters to characterize a cell line is the generation time, i.e. how 
long it takes for a population of cells to duplicate. For this purpose, 1×105 cells were 
seeded in five 25 cm2 flasks and left to adhere for 24 hours at 37°C in a 5% CO2 
atmosphere. In the following two days the flasks were trypsinized and cells were 
counted using 50 µL of cell suspension added to 50 µL of 0.4% trypan blue vital dye 
(1:1). The number of cells in the total volume was calculated using equation 1. The 
results were plotted in a graphic (cell number versus time), from which the generation 
time was calculated using linear regression analysis. 
 
3.2.3.2 In vitro cytotoxicity assays 
 
For the elaboration of cytotoxicity assays, a series of compounds were chosen, 
including novel compounds obtained by chemical synthesis with potential interest for 
topical application: 1,2-dihydroxyxanthone (1,2-DHX), Ascorbic acid persulfate (ASS), 
Chlorogenic acid persulfate (ACS) and Resveratrol Glicoside Sulfate (RGS) 
synthesized in the Pharmaceutical Chemistry Laboratory, FFUP. Resveratrol (RSV), 
Resveratrol Glicoside (RSV-Gli) and C. sativa leaf extract were also characterized.  
RSV loaded nano and micro particles were also analyzed in this work. The 
concentrations tested and solvents are described in Table 6. 
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Table 6: Compounds and their concentrations tested in this work 
 
* concentrations tested in Trypan Blue exclusion assay 
 
 
To assess the cytotoxic effect of the selected compounds on HaCaT cells, five 
cytotoxicity assays were performed after an initial optimization step. For all compounds, 
except the ASS and ACS, cytotoxicity assays were conducted to assess metabolic 
activity (MTT and AlamarBlue® assays), to evaluate the lysosomal integrity (Neutral 
Red assay) and to assess plasma membrane integrity (Trypan Blue and Propidium 
Iodide assay). For ASS and ACS only MTT reduction assay was realized due to the low 
amount compound available. 
All experiments were repeated at least three times. All results from the cytotoxicity 
assays were expressed in percentage of cell viability relatively to positive control (cells 
treated with the solvent) and when applied the concentration able to reduce cell viability 
by 50% (IC50) was calculated using linear regression analysis. 
 
 
3.2.3.2.1 MTT reduction assay 
 
The MTT is a water soluble tetrazolium salt which is reduced to formazan 
(precipitated of violet color) only by metabolically active cells. This assay was 
described with more detail on 1.2.2.2. 
 
 
 
Compounds Solvents Tested concentrations 
1,2-DHX DMSO 12.5*, 25, 50*, 100 and 200* µM 
ASS DMEM 100, 200, 350, 500 and 1000 µM 
ACS DMEM 100, 200, 350, 500 and 1000 µM 
RGS DMEM 100*, 350, 500*, 1000 and 5000* µM 
RSV DMSO 25*, 50, 100, 200*, 350 and 500* µM 
RSV-Gli DMSO 25*, 50, 100, 200*, 350 and 500* µM 
C. sativa leaf extract H2O:Glicerin 
(1:1) 
5*, 50, 100*, 250, 500* µg/mL 
Nano and micro particles DMEM 0.01*, 0.05* and 0.1* % (m/v) 
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 Optimization of the MTT reduction assay conditions 
 
For MTT reduction assay, the optimal cell density was previously selected. For this 
end, cell densities of 2.5×103, 5×103, 1×104, 2×104 and 5×104 cells/well were seeded on 
96 well tissue culture plates (150 µL/well) and incubated at 37°C in a 5% CO2 
atmosphere for 24 hours. The next day, the medium was removed, cells were washed 
one time with DPBS, and fresh culture medium was added and cells were incubated at 
37°C in a 5% CO2 atmosphere for another 24 hours. On the third day, a 5 mg/mL MTT 
stock solution was prepared in DPBS and mixed by vortex until dissolved and then 
diluted 1:10 in serum free DMEM. This solution was protected from light and prepared 
on the day of use. The medium was removed, cells were washed one time with DPBS 
and 150 μL of serum free DMEM containing 0.5 mg/mL MTT was added. After 2 hours 
of incubation incubated at 37°C in a 5% CO2 atmosphere the reagent was removed and 
followed by the addition of 150 μL DMSO to dissolve the formazan crystals. Finally, the 
absorbance of formazan was determined at 570 nm using a plate reader (Biotek 
Instruments, Synergy HT multi-mode microplate reader).  
 
 
 
 Study of the cytotoxic effect of the tested compound’s using 
MTT reduction assay  
 
After optimization of the method, 1×104 cells/well (optimal cell density) were seeded 
and incubated at 37°C in a 5% CO2 atmosphere. After 24 hours of incubation, the 
medium was removed, cells were washed one time with DPBS and different test 
compounds were added and incubated at 37°C in a 5% CO2 atmosphere for another 24 
hours. Ten percent DMSO was used as positive control. On the third day, the 
procedure was the same as described above. 
The results were expressed as the absorbance ratio of treated to control cells:  
 
                  
  
  
        (equation 2) 
 
where As is the absorbance of treated cells and Ac the absorbance of control cells 
(untreated cells). 
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In order to choose the maximum concentration that does not induce cytotoxicity, 
DMSO was tested at different concentrations in this assay. Up to 1% had no influence 
on cell viability in the methods used and so the DMSO concentration did not exceed 
1%. 
 
 
3.2.3.2.2 AlamarBlue® reduction assay 
 
The AlamarBlue® is an oxidized form of redox indicator that is blue in color and non-
fluorescent. When incubated with viable cells, the reagent changes color from blue to 
pink and become fluorescent. This assay was described with more detail on 1.2.2.1. 
 
 Optimization of AlamarBlue® reduction assay conditions 
 
For AlamarBlue® reduction assay, the optimal cell density and incubation time with 
AlamarBlue® were previously optimized. For this purpose, cell densities of 5×103, 
1×104, 2×104 and 4×104 cells/well were seeded on 96 well tissue culture plates (150 
µL/well) and incubated at 37°C in a 5% CO2 atmosphere for 24 hours. The next day, 
the medium was removed, cells were washed one time with DPBS, and fresh culture 
medium was added and cells were incubated 37°C in a 5% CO2 atmosphere for 
another 24 hours. Ten percent AlamarBlue® of the volume in the well was added to 
each well and incubated at 37°C in a 5% CO2 atmosphere. AlamarBlue
® incubation 
times of 1, 2, 3 and 4 hours were tested. Finally, the absorbances at 570 nm (reduced 
form) and 600 nm (oxidized form) were determined using a plate reader. 
The % reduction of AlamarBlue® was calculated using the following equation: 
 
 
                           
               –              
                –               
         (equation 3) 
 
 
 
where: 
 
Eoxi570 = molar extinction coefficient (E) of oxidized AlamarBlue
® at 570nm = 80586  
Eoxi600 = E of oxidized AlamarBlue
® at 600nm = 117216  
A570 = absorbance of test wells at 570nm  
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A600 = absorbance of test wells at 600nm  
Ered570 = E of reduced AlamarBlue
® at 570nm = 155677  
Ered600 = E of reduced AlamarBlue
® at 600nm = 14652  
C570 = absorbance of negative control well (medium, AlamarBlue
®, no cells) at 
570nm  
C600 = absorbance of negative control well (medium, AlamarBlue
®, no cells) at 
600nm 
 
 Study of the cytotoxic effect of the tested compound’s using 
AlamarBlue® reduction assay  
 
After optimization of the method, 2×104 cells/well (optimal cell density) were seeded 
incubated at 37°C in a 5% CO2 atmosphere. After 24 hours of incubation, the medium 
was removed, cells were washed one time with DPBS and the different test 
compounds were added and incubated at 37°C in a 5% CO2 atmosphere for another 24 
hours. Ten percent DMSO was used as positive control. Ten percent AlamarBlue® of 
the volume in the well was added to each well and incubated at 37°C for 4 hours 
(optimal incubation time). Finally, the absorbance at 570 nm and 600 nm was 
determined using a plate reader. 
The % reduction of AlamarBlue® was calculated according to equation 3. 
 
 
3.2.3.2.3 Neutral Red uptake assay 
 
The amount of NR dye incorporated in the cells represents lysosomal functionality, 
as this dye easily penetrates viable cell membranes and accumulates intracellularly in 
lysosomes. This assay was described with more detail on 1.2.1.4. 
 
 Optimization of NR uptake assay conditions 
 
For NR uptake assay, the optimal cell density, the concentration of the NR solution 
and the incubation time with NR were previously optimized. For this purpose, 2.5×103, 
5×103, 1×104, 2×104 and 5×104 cells/well were seeded on 96 tissue culture well plates 
(150 µL/well) and incubated at 37°C in a 5% CO2 atmosphere for 24 hours. The next 
day, the medium was removed, cells were washed one time with DPBS, and fresh 
culture medium was added and incubated at 37°C in a 5% CO2 atmosphere for another 
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24 hours. The medium was removed, cells were washed one time with DPBS and 150 
μL of culture medium containing 33, 50, 100 and 330 µg/mL NR solution were added to 
each well and incubated at 37°C in a 5% CO2 atmosphere. NR incubation times of 2, 3 
and 4 hours were tested. NR tends to precipitate, so the medium with stain was 
incubated at 37°C in a 5% CO2 atmosphere protected from light overnight, centrifuged 
at 1500 g for 10 minutes and filtered (5 μm) before use. After incubation time, NR 
solution was removed, cells were washed one time with DPBS at 37°C and 150 μL/well 
of the solution formed by 50% ethanol/1% acetic acid was added to extract the NR dye 
meanwhile captured within the cells. The plates were then placed in a microplate 
shaker for 10 minutes, at room temperature and protected from light. Finally, 
absorbance was measured at 540 nm. 
 
 
 Study of the cytotoxic effect of the tested compound’s using 
NR uptake assay  
 
After optimization of the method, 2×104 cells/well (optimal cell density) were seeded 
and incubated at 37°C in a 5% CO2 atmosphere. After 24 hours of incubation, the 
medium was removed, cells were washed one time DPBS and different test 
compounds were added and incubated at 37°C in a 5% CO2 atmosphere for another 24 
hours. Ten percent DMSO was used as positive control. The medium was removed, 
cells were washed one time with DPBS at 37°C and 150 μL of complete DMEM 
containing 50 µg/mL NR (optimal concentration) was added to each well and incubated 
for 3 hours (optimal incubation time) protected from light. After incubation time, NR 
solution was removed, cells were washed one time with DPBS and 150 μL/well of the 
solution formed by 50% ethanol/1% acetic acid was added to extract the NR dye 
meanwhile captured within the cells. The plates were then placed in a microplate 
shaker for 10 min, at room temperature and protected from light. Finally absorbance 
was measured at 540 nm. 
The results were expressed as the absorbance ratio of treated to control cells, 
using Equation 2. 
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3.2.3.2.4 Trypan Blue exclusion assay 
 
The trypan blue is a vital stain used to stain dead cells. This assay was described 
with more detail on 1.2.1.6. 
 
 Optimization of Trypan Blue exclusion assay conditions 
 
For Trypan Blue dye exclusion assay, the optimal cell density was previously 
selected. For this end, cell densities of 1×104, 2×104, 5×104, 1×105, 2×105 and 3.5×105 
cells/well were seeded on 12 well culture plates (1 mL/well) and incubated at 37°C in a 
5% CO2 atmosphere for 24 hours. The next day, the medium was removed, cells were 
washed one time with DPBS, and fresh culture medium was added and cells were 
incubated at 37°C in a 5% CO2 atmosphere for another 24h. Then the contents of the 
wells were transferred into conical tubes, wells were washed one time with DPBS and 
also transferred into conical tubes. Then, the cells were detached from the bottom of 
the wells by the action of trypsin after 5-12 minutes and were centrifuged at 416 g for 5 
minutes at room temperature. Cells were counted using 50 µL of cell suspension added 
to 50 µL of 0.4% trypan blue vital dye (1:1).  
 
 Study of the cytotoxic effect of the tested compound’s using 
Trypan Blue exclusion assay  
 
After optimization of the method, 1×105 cells/well (optimal cell density) were seeded 
and incubated at 37°C in a 5% CO2 atmosphere. After 24 hours of incubation, the 
medium was removed, cells were washed one time DPBS and different test 
compounds were added and incubated at 37°C for another 24 hours. Ten percent 
DMSO and 15% ethanol 70º were tested as positive control. On the third day, the 
procedure was the same as described above. 
The % cell viability was calculated according to: 
 
 
                  
            
                  
         (equation 4) 
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3.2.3.2.5 Propidium Iodide exclusion assay 
 
PI is a dye that does not pass through intact cell membranes. This assay was 
described with more detail on 1.2.1.5. 
 
 Study of the cytotoxic effect of the tested compound’s using 
Propidium Iodide exclusion assay  
 
Using the cell density previously optimized for Trypan Blue dye exclusion assay, 
1×105 cells/well were seeded and incubated at 37°C in a 5% CO2 atmosphere. After 24 
hours of incubation at 37°C in a 5% CO2 atmosphere, the medium was removed, cells 
were washed one time DPBS and different test compounds were added and incubated 
at 37°C in a 5% CO2 atmosphere for another 24 hours. Ten percent DMSO and 0.1% 
Triton X-100 were tested as positive control. On the third day, the contents of the wells 
were transferred into conical tubes, wells were washed one time with DPBS and also 
transferred into conical tubes. Then, the cells were detached from the bottom of the 
wells by the action of trypsin after 8 minutes (optimized incubation time), complete 
DMEM was added to stop the action of trypsin and the content was centrifuged at 416 
g for 5 minutes at room temperature. The supernatant was discarded and the cells 
washed two times by addition of cold 5 mL of DPBS + 2% FBS, centrifuging at 416 g 
for 6 minutes at a temperature of 4°C. Then, the supernatant was aspirated and the 
cells were ressuspended in 100 μL of cold DPBS. Content was transferred to 2 mL 
tubes and, finally, stained with 5 μL of PI working solution [10 μL of stock solution (10 
mg of PI + 10 mL of Milli Q water) in 1 mL of DPBS] 5 minutes before starting the 
analysis. Cells were acquired on the flow cytometer BD AccuriTM C6 and at least ten 
thousand events were analyzed on the basis of size, complexity and emission of 
orange fluorescence, by setting up instrument settings for FSC, SSC and FL-2 and by 
using stained and unstained cells. Data were analyzed by using the BD AccuriTM C6 
software version 1.0.264.21. 
 
 
3.2.4 Statistical analysis 
 
The data is presented as mean ± standard deviation (SD) of at least three 
independent experiments. Statistical analysis was carried out using One-way analysis 
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of variance (ANOVA) followed by the Dunnett post hoc test (comparison to negative 
control), after confirming normality and homogeneity of variance with Shapiro-Wilk and 
Levene tests, respectively. Comparisons between loaded and empty nanoparticles 
were performed with the Tukey post hoc test. Statistical significance was considered 
when p < 0.05.  
All statistical analyses were performed using the SPSS software (v 23.0; IBM, 
Armonk, NY, USA) and graphs were generated by GraphPad Prism for Windows 
(version 6.0; GraphPad Software, Inc., USA). 
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4. RESULTS 
 
4.1 Qualitative analysis of the phenolic composition of  
C. sativa leaf extract 
 
Plant extracts are complex mixtures that include various compounds that may 
contribute to a particular biologic effect. Scavenging activity found for several reactive 
oxygen species by C. sativa EtOH:water (7:3) leaf extract and characterization of the  
phenolic compounds present in this extract have been documented previously [111].  
HPLC analysis of the obtained extract was carried out to confirm the presence of 
these compounds and the results are shown in Figure 16. 
Based on UV/Vis spectra and retention times of each compound and comparison 
with data obtained previously for this extract, it was possible to identify the main 
phenolic compounds of interest, such as: chlorogenic acid, hyperoside, rutin, 
isoquercitrin and ellagic acid. Hyperoside, isoquercitrin and rutin present co-elution, as 
a result of their structural affinity [113]. 
 
 
 
Figure 16: HPLC phenolic profile of C. sativa leaf extract. Detection at 350 nm. (1) chlorogenic acid; (2) hyperoside; 
(3) rutin; (4) isoquercitrin; and (5) ellagic acid. Based on [113]. 
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4.2 Particle size measurements 
 
The particle size was verified by measuring the particle size distribution using laser 
diffractometry. The mean size (Dv10, Dv50 and Dv90) of the lipid nanoparticles and 
polymeric microparticles, are presented in Table 7 and Table 8, respectively. Span 
refers to the bandwidth of the size distribution and it is determined by the following 
equation: 
 
      
     –    
    
    (equation 5) 
 
Table 7: Lipid nanoparticles size measurements after preparation. The results are expressed as mean ± SD of 
different batches (n=14-21) 
  Dv10 Mean ± SD 
[nm]   
 Dv50 Mean ± SD 
[nm]    
 Dv90 Mean ± SD 
[nm]    
 Span Mean ± SD  
 
SLN empty 124 ± 23 283 ± 39 720 ± 99 2.165 ± 0.570 
SLN-RSV 134 ± 26 296 ± 53 707 ± 149 1.971 ± 0.543 
NLC empty 160 ± 19 369 ± 61 1074 ± 459 2.374 ± 0.719 
NLC-RSV 140 ± 16 305 ± 40 746 ± 247 1.938 ± 0.450 
 
 
Table 8: Polymeric microparticles size measurements after preparation. The results are expressed as mean ± SD 
of different batches (n=2) 
  Dv10 Mean ± SD 
[μm]  
 Dv50 Mean ± SD 
[μm] 
Dv90 Mean ± SD 
[μm] 
Span Mean ± SD  
 
Poly empty 0.691 ± 0.035 3.930 ± 0.651 15.650 ± 3.889 3.775 ± 0.352 
Poly-RSV 2.070 ± 0.933 5.585 ± 1.860 14.500 ± 0.424 2.378 ± 0.882 
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4.3 Characterization of the HaCaT cell line 
 
In Figure 17 depicts the results obtained for the determination of doubling time of 
HaCaT cells. 
The calculated generation time was 23.82 hours. In the work by Rekus, of the 
generation time in HaCaT cells was approximately 26 hours [116]. 
 
 
 
Figure 17: Determination of HaCaT cells doubling time by linear regression analysis. 
 
 
4.4 In vitro cytotoxicity assays 
 
The main objective of this work was to evaluate the cytotoxic effect of several 
compounds with putative interest for topical application. For this purpose, MTT 
reduction, AlamarBlue® reduction, NR uptake, Trypan Blue exclusion and Propidium 
iodide exclusion in vitro assays were used. 
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4.4.1 MTT reduction assay 
 
The yellow tetrazolium MTT is reduced by metabolically active cells. The resulting 
intracellular purple formazan can be solubilized and quantified by spectrophotometric 
means and is thus directly proportional to the cell viability.  
 
 Optimization of the MTT reduction assay conditions  
 
Before assessing the cytotoxic effect of the selected compounds with the MTT 
reduction assay, different cell densities of HaCaT cells were tested in order to choose 
the optimal cell density. Through the analysis of Figure 18, the density of 1×105 
cells/well was chosen because it provided an absorbance lower than 1.0 AU (0.797 
AU) and within the linear range. This also contributes to a proper sensitivity of the 
method of assessment of cytotoxicity.  
 
 
Figure 18: Evaluation of the linearity of the MTT reduction assay in function of HaCaT cell density. 
 
 Study of the cytotoxic effect of the tested compound’s 
using MTT reduction assay 
 
After choosing the optimal cell density for MTT reduction assay, the selected 
compounds were tested. Figure 19 shows the results of the viability assay for RSV 
and its derivatives. A significant decrease in cell viability occurred for cells exposed 
from the concentration of 100 μM for RSV (A) and at 5000 μM for RGS (C) when 
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compared to cells treated with the solvent (negative control). RSV-Gli (B) did not 
induce significant alterations of HaCaT cells viability.  
For the positive control (10% DMSO) HaCaT cells showed a cell viability of 12.67 ± 
4.21%. 
 
 
 
Figure 19: Cell viability of HaCaT cell line exposed to (A) RSV, (B) RSV-Gli and (C) RGS, determined by the MTT 
reduction assay. Results were calculated as percentage of negative control (cells treated with the solvent). Data are 
presented as mean ± SD (n=3-9). Data were analyzed using One-way ANOVA with Dunnett post hoc test. * P<0.05 data 
are significantly different from the control value. 
 
 
Figure 20 shows the results of the viability assay for lipid nanoparticles. Both the 
loaded and the empty nanoparticles in all tested concentrations showed a significant 
decrease in cell viability. A concentration-dependent decrease is observed mainly for 
SLN particles. 
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Figure 20: Cell viability of HaCaT cell line exposed to (A) SLN empty and SLN-RSV and (B) NLC empty and NLC-
RSV, determined by the MTT reduction assay. Results were calculated as percentage of negative control (cells treated 
with the solvent). Data are presented as mean ± SD (n=3-9). Data were analyzed using One-way ANOVA with Dunnett 
post hoc test. * P<0.05 data are significantly different from the control value. Comparisons between loaded and empty 
nanoparticles were performed with the Tukey post hoc test. ** P<0.05 data are statistically different. 
 
 
In addition to the lipid nanoparticles, polymeric microparticles were also tested with 
the MTT reduction assay. However, the deposition of the microparticles on the surface 
of the cell monolayer and microparticle aggregation (as shown in Figure 21) led to a 
great variability of the results. For this reason, these particles were not included on 
subsequent cytotoxicity tests.  
 
 
 
 
 
 
 
 
Figure 21: Observation under inverted microscope of HaCaT cell line with 
0.01% polymeric microparticles after 24 hours incubation (10X magnification). 
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Figure 22 and 23 show the cell viability results for two of the compounds obtained 
by chemical synthesis, ASS and ACS, respectively.  ASS caused significant cytotoxicity 
for all tested concentrations when compared to negative control, being the highest 
concentration tested (5000 μM) able to decrease the levels of viability to 62.49 ± 
6.24%. A concentration-dependent effect was not found. For ACS, a significant 
decrease in cell viability has been detected from the concentration of 500 μM when 
compared to the negative control. For this compound, a concentration-dependent 
decrease of cell viability was observed. 
As already mentioned, these two compounds were not tested with the remaining 
cytotoxicity assays due to the small amount available. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Cell viability of HaCaT cell line exposed to ASS, determined by the MTT reduction assay. Results were 
calculated as percentage of negative control (cells treated with the solvent). Data are presented as mean ± SD (n=3-9). 
Data were analyzed using One-way ANOVA with Dunnett post hoc test. * P<0.05 data are significantly different from the 
control value. 
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Figure 24 shows the cell viability results obtained for 1,2-DHX. After the 24h 
incubation with HaCaT cells, 1,2-DHX caused a significant decrease in cell viability 
from the concentration of 100 μM. The cell viability was 36.14 ± 7.44% for HaCaT cells 
exposed to the concentration of 200 μM.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: Cell viability of HaCaT cell line exposed to ACS, determined by the MTT reduction assay. Results were 
calculated as percentage of negative control (cells treated with the solvent). Data are presented as mean ± SD (n=3-9). 
Data were analyzed using One-way ANOVA with Dunnett post hoc test. * P<0.05 data are significantly different from the 
control value. 
Figure 24:  Cell viability of HaCaT cell line exposed to 1,2-DHX, determined by the MTT reduction assay. Results 
were calculated as percentage of negative control (cells treated with the solvent). Data are presented as mean ± SD 
(n=3-9). Data were analyzed using One-way ANOVA with Dunnett post hoc test. * P<0.05 data are significantly different 
from the control value. 
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The ability of C.sativa EtOH:water (7:3) leaf extract to interfere with cell viability of 
the HaCaT cells after 24 hours incubation was evaluated. The Figure 25 shows that 
C.sativa extract caused significant cytotoxicity when compared to negative control only 
at the concentration of 500 μg/mL. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 25: Cell viability of HaCaT cell line exposed to C.sativa leaf extract, determined by the MTT reduction assay. 
Results were calculated as percentage of negative control (cells treated with the solvent). Data are presented as mean ± SD 
(n=3-9). Data were analyzed using One-way ANOVA with Dunnett post hoc test. * P<0.05 data are significantly different from 
the control value. 
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4.4.2 AlamarBlue® reduction assay 
 
The AlamarBlue® reagent has as active ingredient rezasurin, a cell permeable 
compound that is blue in color and virtually non-fluorescent. Upon entering cells, 
resazurin is reduced to resorufin, a compound that is pink in color and highly 
fluorescent.  
 
 Optimization of the AlamarBlue® reduction assay 
conditions  
 
Before assessing the cytotoxic effect of the selected compounds with the 
AlamarBlue® reduction assay, different cell densities of HaCaT cells and different 
incubation times with AlamarBlue® were tested. Figure 26 shows the results obtained 
on this optimization step.  
The reduction of AlamarBlue® increased with increasing cell density up to the 
density of 2×105 cells/well, from this value, a plateau is reached. The reduction of 
AlamarBlue® also increased with increasing incubation time. Given all the results, the 
chosen test conditions were: cell density of 2×105 cells/well and incubation time of 4 
hours. 
 
 
 
Figure 26: Graph of  % reduced of AlamarBlue
®
 obtained for HaCaT cell line. (A) % reduction of AlamarBlue
®
 in 
function of the cell density and (B) % reduction of AlamarBlue
®
 in function of the incubation time with AlamarBlue
®
. 
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 Study of the cytotoxic effect of the tested compound’s 
using AlamarBlue® reduction assay 
 
After choosing the optimal cell density and incubation time for AlamarBlue® 
reduction assay, the selected compounds were tested. Figure 27 shows the results of 
viability assay for RSV and its derivatives. A concentration-dependent decrease in cell 
viability was observed for RSV (A). A significant decrease in viability of cells occurred 
after exposure to RSV concentrations of 350 and 500 μM (A). For RSV-Gli (B) and 
RGS (C) no significant alterations of HaCaT cell viability were detected. 
HaCaT cells incubated with positive control showed a cell viability of the 7.56 ± 
6.29%. 
 
 
 
 
Figure 27: Cell viability of HaCaT cell line exposed to (A) RSV, (B) RSV-Gli and (C) RGS, determined by the 
AlamarBlue
®
 reduction assay. Results were calculated as percentage of negative control (cells treated with the solvent). 
Data are presented as mean ± SD (n=3-9). Data were analyzed using One-way ANOVA with Dunnett post hoc test. * 
P<0.05 data are significantly different from the control value. 
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Figure 28 shows the results of HaCaT cells exposed 24 hours with the lipid 
nanoparticles. The concentrations 0.1% SLN empty, 0.05% and 0.1% SLN-RSV 
showed a significant decrease in cell viability. In turn, 0.01% SLN increases the cell 
viability, under present experimental conditions. Empty and drug-loaded NLC did not 
induce significant alterations in HaCaT cell viability. 
 
 
Figure 28: Cell viability of HaCaT cell line exposed to (A) SLN empty and SLN-RSV and (B) NLC empty and NLC-
RSV, determined by the AlamarBlue®
 
reduction assay. Results were calculated as percentage of negative control (cells 
treated with the solvent). Data are presented as mean ± SD (n=3-9). Data were analyzed using One-way ANOVA with 
Dunnett post hoc test. * P<0.05 data are significantly different from the control value. Comparisons between loaded and 
empty nanoparticles were performed with the Tukey post hoc test. ** P<0.05 data are statistically different. 
One of the distinct features of the experimental protocol of this assay is the 
absence of a washing step before measuring the absorbance. This results in the 
contribution of the optical density properties of the tested compounds to the measured 
absorbance. This was particularly relevant for lipid nanoparticles since they are 
dispersed in cell medium and for the higher concentrations, absorbance results higher 
than 1 UA were found. 
Figure 29 shows the cell viability results obtained for 1,2-DHX. This xanthone 
caused a significant decrease in cell viability only at the concentration of 200 μM. The 
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cell viability was 54.51 ± 13.53% for HaCaT cells exposed to the concentration of 200 
μM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Figure 30 shows the results obtained for extract plant. In general, C. sativa leaf 
extract did not induce significant alterations of HaCaT cells, when available with 
AlamarBlue® reduction assay. 
 
 
 
 
 
 
 
 
 
 
Figure 29: Cell viability of HaCaT cell line exposed to 1,2-DHX, determined by the AlamarBlue® reduction assay. 
Results were calculated as percentage of negative control (cells treated with the solvent). Data are presented as mean 
± SD (n=3-9). Data were analyzed using One-way ANOVA with Dunnett post hoc test. * P<0.05 data are significantly 
different from the control value. 
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4.4.3 Neutral Red uptake assay 
 
The NR uptake assay was used to assess the integrity of the lysosomal membrane. 
Viable cells take up the dye by passive transport and incorporate the dye into 
lysosomes, whereas non-viable cells do not take up the dye. Thus, a decrease in NR 
cell content indicates damage of the lysosome and suggests a decrease in cell viability. 
 
 Optimization of the NR uptake assay conditions  
 
Before assessing the cytotoxic effect of the selected compounds with the NR 
uptake assay, different cell densities of HaCaT cells, concentrations of the NR solution 
and incubation times with NR solution were tested.  
Selection of the appropriate final concentration of NR solution was based on the 
observation under inverted microscope of the different concentrations tested. For 
concentrations of 100 and 330 μg/mL the formation of crystals was observed, unlike 
concentrations of 33 and 50 μg/mL, as shown in Figure 31.  
Figure 30: Cell viability of HaCaT cell line exposed to C.sativa leaf extract, determined by the AlamarBlue® reduction 
assay. Results were calculated as percentage of negative control (cells treated with the solvent). Data are presented as 
mean ± SD (n=3-9). Data were analyzed using One-way ANOVA with Dunnett post hoc test. * P<0.05 data are 
significantly different from the control value. 
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Figure 32 depicts the results obtained for the different cell densities and incubation 
times tested.  
 
Figure 31: Observation under inverted microscope of HaCaT cell line in different tested concentrations 
the NR solution (10X magnification). 
Figure 32: Graph of absorbance values obtained for different tested cell density, final concentration of the Neutral Red and 
incubation time with NR solution. (A) NR 33 μg/mL (B) NR 50 μg/mL (C) NR 100 μg/mL and (D) NR 330 μg/mL. 
58 FCUP/ICBAS 
Study of the cytotoxicity of raw materials of cosmetic and topical pharmaceutical formulations  
 
Given all the results, the chosen test conditions were: density of 2×105 cells/well, 
NR solution concentration of 50 μg/mL and incubation time of 3 hours. 
 
 Study of the cytotoxic effect of the tested compound’s 
using NR uptake assay 
 
After choosing the optimal cell density of HaCaT cells, concentration of the NR 
solution and optimal incubation time for this assay, the selected compounds were 
tested. Figure 33 shows the results of viability assays using RSV and its derivatives. 
RSV (A) at concentration of 25 μM already caused significant cytotoxicity when 
compared to control cells, being the highest concentration tested (500 μM) able to 
decrease the levels NR uptake to 35.67 ± 8.17%. For RSV-Gli (B) and RGS (C) no 
significant alterations of HaCaT cells viability were detected in the range of 
concentrations tested. 
The positive control caused a viability cell of the 14.55 ± 2.24%. 
 
 
Figure 33: Cell viability of HaCaT cell line exposed to (A) RSV, (B) RSV-Gli and (C) RGS, 
determined by the NR uptake assay. Results were calculated as percentage of negative control (cells 
treated with the solvent). Data are presented as mean ± SD (n=3-9). Data were analyzed using One-way 
ANOVA with Dunnett post hoc test. * P<0.05 data are significantly different from the control value. 
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Figure 34 shows the results of cell viability obtained with HaCaT cells exposed 24 
hours with lipid nanoparticles. Regarding the SLN, there was a significant decrease in 
cell viability to 0.05% and 0.1% concentrations. For these lipid nanoparticles, a 
concentration-dependent decrease of cell viability was observed. Already the NLC 
showed significant decrease in cell viability for 0.1% NLC empty, 0.05% and 0.1% 
NLC-RSV. It is also important to underline the significant difference between the empty 
NLC and loaded-NLC with RSV for concentrations of 0.05% and 0.1%. 
 
 
 
Figure 34: Cell viability of HaCaT cell line exposed to (A) SLN empty and SLN-RSV and (B) NLC empty and NLC-
RSV, determined by the NR uptake assay. Results were calculated as percentage of negative control (cells treated with 
the solvent). Data are presented as mean ± SD (n=3-9). Data were analyzed using One-way ANOVA with Dunnett post 
hoc test. * P<0.05 data are significantly different from the control value. Comparisons between loaded and empty 
nanoparticles were performed with the Tukey post hoc test. ** P<0.05 data are statistically different. 
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Figure 35 shows the cell viability results obtained for 1,2-DHX, after the 24h 
incubation with HaCaT cells. 1,2-DHX caused a significant decrease in cell viability 
from the concentration 50 μM when compared to negative control. For the highest 
concentration tested (200 μM) the cell viability was 41.96 ± 4.57%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36 shows the cell viability results obtained for plant extract utilized in this 
work. C.sativa leaf extract at concentrations of 250 and 500 μg/mL promoted a 
significant decrease in HaCaT cell viability in comparison to negative control. The 
viability was 56.13 ± 3.80% for cells exposed to concentration of 500 μg/mL. 
 
 
 
 
 
 
 
Figure 35: Cell viability of HaCaT cell line exposed to 1,2-DHX, determined by the NR uptake assay. Results were 
calculated as percentage of negative control (cells treated with the solvent). Data are presented as mean ± SD (n=3-9). Data 
were analyzed using One-way ANOVA with Dunnett post hoc test. * P<0.05 data are significantly different from the control 
value. 
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4.4.4 Trypan Blue exclusion assay 
 
The Trypan Blue exclusion assay was used to assess the integrity of the plasma 
membrane. This assay is based on the principle that the intact plasma membranes of 
live cells exclude trypan blue, whereas the dead cells do not. 
 
 Optimization of the Trypan Blue exclusion assay 
conditions  
 
Before assessing the cytotoxic effect of the selected compounds with the Trypan 
Blue exclusion assay, different cell densities of HaCaT cells were tested in order to 
choose the optimal cell density. Selection of the appropriate cell density for this assay 
was based on the observation under inverted microscope of the different cell densities 
tested. 
Through the analysis of the Figure 37, with regard to confluence obtained for each 
cell density, 1×105 cells/well was chosen. 
Figure 36: Cell viability of HaCaT cell line exposed to C.sativa leaft extract, determined by the NR uptake assay. 
Results were calculated as percentage of negative control (cells treated with the solvent). Data are presented as mean ± 
SD (n=3-9). Data were analyzed using One-way ANOVA with Dunnett post hoc test. * P<0.05 data are significantly different 
from the control value. 
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Beyond the choice of the appropriate cell density, it was also necessary to test the 
positive control. While in the above cytotoxicity assays 10% DMSO proved to be a 
good positive control, for trypan blue reduction assay this was not verified. With 10% 
DMSO the cells detached and fragmented, which made it impossible to count them 
(Figure 38). In addition, 15% ethanol 70º was also tested, but only dead cells were 
counted and the number of total cells was reduced drastically, so it was decided not to 
include a positive control in our results. 
 
Figure 37: Observation under inverted microscope of HaCaT cell line in different tested cell densities, after 48 
hours incubation (10X magnification). 
Figure 38: Observation under inverted microscope of HaCaT cell line with 10% DMSO after 24 hours 
incubation (10X magnification). 
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 Study of the cytotoxic effect of the tested compound’s 
using Trypan Blue exclusion assay 
 
After choosing the optimal cell density for trypan blue exclusion assay, the 
selected compounds were tested. Figure 39 shows the results of the viability assay 
for RSV and its derivatives. A significant decrease in cell viability occurred for HaCaT 
cells exposed from the concentration 200 μM for RSV (A) and at 5000 μM for RGS (C). 
RSV-Gli (B) did not induce significant alterations of HaCaT cells viability.  
 
 
 
  
 
Figure 39: Cell viability of HaCaT cell line exposed to (A) RSV, (B) RSV-Gli and (C) RGS, determined by the 
Trypan Blue exclusion. Data are presented as mean ± SD (n=3-9). Data were analyzed using One-way ANOVA 
with Dunnett post hoc test. * P<0.05 data are significantly different from the control value. 
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Figure 40 show the results of cell viability of HaCaT cells after 24 hours incubation 
with lipid nanoparticles. Regarding the SLN, a significant decrease in cell viability to 
concentration 0.1% SLN empty, 0.05% and 0.1% SLN-RSV was observed. Already the 
NLC showed significant decrease in cell viability for concentration 0.1%. 
 
 
 
Figure 40: Cell viability of HaCaT cell line exposed to (A) SLN and SLN-RSV and (B) NLC and NLC-RSV, 
determined by the Trypan Blue exclusion assay. Data is presented as mean ± SD (n=3-9). Data were analyzed using 
One-way ANOVA with Dunnett post hoc test. * P<0.05 data are significantly different from the control value. 
Comparisons between loaded and empty nanoparticles were performed with the Tukey post hoc test. ** P<0.05 data are 
statistically different. 
 
 
Results of the 1,2-DHX after 24 hours of incubation with HaCaT cells are shown in 
Figure 41. A significant decrease in the cell viability is detected with 200 μM 
concentration. For this concentration the cell viability was 74.29 ± 12.54%. 
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Results of cell viability of HaCaT cells after 24 hours incubation with C.sativa leaf 
extract are shown in Figure 42 and no significant alterations of cells viability were 
detected in the range of concentrations tested. There were some difficulties in evaluate 
the cytotoxic effects of this compound by Trypan blue exclusion assay. Indeed, after 
microscope analysis without the dye addition, dead cells were observed. Probably the 
solvent used, glycerin, may interfere with the density of the suspension leading to 
unsuitable centrifugation time and g-force that may damage the cells. 
 
 
 
 
 
 
 
 
 
 
Figure 41: Cell viability of HaCaT cell line exposed to 1,2-DHX, determined by the Trypan Blue exclusion assay.  
Data are presented as mean ± SD (n=3-9). Data were analyzed using One-way ANOVA with Dunnett post hoc test. * 
P<0.05 data are significantly different from the control value. 
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4.4.5 Propidium Iodide exclusion assay 
 
Propidium iodide is a dye that does not pass through intact cell membranes, is 
generally excluded from viable cells. 
Representative histograms obtained by flow cytometry for unstained cells and cells 
stained with PI are shown in Figure 43. The results showed that the negative control 
(untreated cells) presented a very high rate of PI incorporation probably due its high 
concentration. Optimization of several protocol conditions, including the PI and cell 
concentration, was needed and was not achieved due to time restrictions. Therefore 
we chose not to test the compounds with this methodology.  
 
 
 
Figure 42: Cell viability of HaCaT cell line exposed to C.sativa leaf extract, determined by the Trypan Blue exclusion 
assay. Data are presented as mean ± SD (n=3-9). Data were analyzed using One-way ANOVA with Dunnett post hoc 
test. * P<0.05 data are significantly different from the control value. 
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4.4.6 Comparison between the results of the different in 
vitro cytotoxicity assays 
 
  The IC50 values for cytotoxic effect and values of the lowest concentration that 
promote a significance statistically decrease to the initially cell viability, depending on 
the assay used are represented in Table 9. 
For the chemicals and the plant extract tested on this work, MTT reduction and NR 
uptake assays presented higher sensitivity compared to the other assays. The toxicity 
was observed with NR uptake assays at lower concentrations, except for RGS and 
lower IC50 values were found with the MTT reduction assay. It should be noticed 
however that these assays were performed with different conditions such as different 
cell densities according to the results of the optimization step. 
A wide variability was observed for all lipid nanoparticles which is a manifestation of 
the difficulties of analyzing their cytotoxicity in vitro. 
Figure 43: Representative histograms of unstained cells (A) PI stained cells (B) obtained by flow 
cytometry (BD ACCURI C6 software). 
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Table 9: IC50 values and the values of the lowest concentration that promote a significance statistically decrease to the initially cell viability for different cytotoxicity assays used in HaCaT cell line 
Cytotoxicity assays MTT reduction AlamarBlue
® reduction Neutral Red uptake Trypan Blue exclusion 
IC50 ± SD * IC50 ± SD * IC50 ± SD * IC50 ± SD * 
SLN empty 0.031 ± 0.021 
% 
0.01 % > 0.1 % 0.01 % 0.084 ± 0.011 
% 
0.05 % > 0.1 % 0.1 % 
SLN-RSV ND 0.01 % > 0.1 % 0.05 % 0.077 ± 0.010 
% 
0.05 % > 0.1 % 0.05 % 
NLC empty 0.074 ± 0.020 
% 
0.01 % > 0.1 % - > 0.1% 0.1 % > 0.1 % 0.1 % 
NLC-RSV 0.085 ± 0.005 
% 
0.01 % > 0.1 % - > 0.1% 0.05 % > 0.1 % 0.1 % 
1,2-DHX 155.43 ± 8.15 
µM 
100 µM > 200 µM 200 µM 172.40 ± 14.37 
µM 
50 µM > 200 µM 200 µM 
C. sativa leaf extract 479.19 ± 14.90  
µg/mL 
500 µg/mL > 500 µg/mL - > 500 µg/mL 250 µg/mL > 500 µg/mL - 
RSV 174.47 ± 11.18 
µM 
100 µM 387.27 ± 6.88 
µM 
350 µM 383.19 ± 53.81 
µM 
25 µM 412.62 ± 14.79 
µM 
200 µM 
RGS > 5000 µM 5000 µM > 5000 µM - > 5000 µM - > 5000 µM 5000 µM 
RSV-Gli > 500 µM - > 500 µM - > 500 µM - > 500 µM - 
ACS > 5000 µM 500 µM 
ASS > 5000 µM 100 µM 
* is the lowest concentration that promote a significance statistically decrease to the initially cell viability. 
ND: not defined 
( - ) indicates no statistically significance obtained.  
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5. DISCUSSION 
 
In the present work, the cytotoxicity of a series of ingredients with potential interest 
for topical application was studied. This study was performed in HaCaT cells, an 
immortal non-cancerous human keratinocyte cell line. Keratinocytes are the 
predominant cells in the first layers of the skin, the epidermis. Considering the intended 
route of administration for these materials, using a human keratinocyte cell line for their 
preliminary safety evaluation is a logical choice.  
Toxicological testing is a regulatory requirement for cosmetic and pharmaceutical 
products. For cosmetics, each ingredient included in the cosmetic product must 
undergo toxicological evaluation, such as, local toxicity and corrosivity evaluation (skin 
and eye irritation), skin sensitization, dermal/percutaneous absorption, among others. 
In the case of the pharmaceutical products, beyond toxicological requirements, other 
nonclinical studies include pharmacology studies (e.g. cardiovascular, central nervous, 
respiratory systems) are required.  
To investigate the potential cytotoxic effects of a series of ingredients on HaCaT 
cells, different cytotoxicity assays were performed (MTT reduction, AlamarBlue® 
reduction, NR uptake and Trypan Blue exclusion). Cytotoxicity assays are widely used 
in preliminary investigation of the toxicity, since they provide an important advantage in 
identification of the cytotoxic compounds [83]. These assays allow determining whether 
a compound or extract contains significant quantities of biologically harmful chemicals, 
therefore are useful for screening as they serve to separate toxic from nontoxic 
materials, providing predictive evidence of compound safety [82]. Toxicity assays are 
essentials for a process of screening large chemical libraries easier, however the 
selection of one cytotoxicity assay over another can be troublesome due to the 
availability of several assays that rely on different physiological mechanisms and 
endpoints [117].  
When comparing the four cytotoxicity assays employed in this work to assess a 
series of ingredients with potential interest for topical application, it is obvious that the 
results obtained are not in close agreement. This can be explained by the different 
mechanism assessed, except in case of the MTT and AlamarBlue® assays which both 
measure the metabolic activity. In turn, NR and trypan blue assess the lysosomal 
integrity and cell membrane damage, respectively. It has been previously reported that 
different cytotoxicity assays can give different results depending on the test agent used 
and the cytotoxicity assay employed [59]. Kim and co-workers showed no correlation 
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between MTT reduction and trypan Blue exclusion assays for the tested compounds 
[118].  
In this work, NR and MTT assays were the most sensitive in detecting toxic effects 
compared to the other assays utilized since the toxicity was observed with NR assay at 
lower concentrations, except for RGS, and lower IC50 values were found with the MTT 
assay. These differences among cytotoxicity assays may suggest that the intracellular 
effects due to exposure to compounds occur before any permanent cell membrane 
damage occur. There are evidences in which these two assays were also more 
sensitive when compared with LDH leakage and protein assays [38]. MTT reduction 
assay also was more sensitive in a study performed in HaCaT cells [119]. However in 
this study, the cell concentration used to perform the MTT test was lower than the one 
used for the other tests, thus we cannot exclude the fact that the inferior IC50 values 
obtained for the MTT assay might be due to the cells being exposed to higher levels of 
the compounds. This evidence emphasizes the need to be careful when comparing 
different cytotoxicity tests. In the case of NR assay, this dye uptake by cells occurs 
through a process requiring energy, being sensitive to substances that interfere with 
cell membrane and lysosomal permeability as well as the process of energy-dependent 
endocytosis [120], therefore expectable to be one of the most sensitive test.  
RSV a compound know as a strong antioxidant [121], anti-inflammatory [122] and a 
cardioprotective agent [123], showed in general a significant decrease in cell viability 
from the concentration of 100 μM, except in the NR reduction assay.  In this assay, 
exposure to RSV at 25 μM already caused a significant decrease in cell viability 
comparing to control, which was not dependent on the concentration up to 100 μM.  
Noteworthy, cell viability found in such cases was around 80%, which can be 
considered non-cytotoxic [124]. A study performed in a primary keratinocyte line 
showed that RSV did not induce significant cytotoxicity up to 50 μM [125], which is 
consistent with the majority of our results. Other studies have revealed that RSV 
inhibits the proliferation of normal human keratinocytes in vitro [125, 126].  Although it 
was not the aim of our study, in the Trypan Blue exclusion assay it was also found that 
after exposure to RSV at 25 μM the number of viable cells was lower than the one 
found for the control, even if no decrease in cell viability was observed.  This putative 
anti-proliferative effect could be a confounding factor in the analysis of cytotoxicity 
results, as is the case of NR reduction assay. 
Two RSV derivatives were also studied in this work. RSV-Gli was the only 
compound studied in this work that showed no cytotoxicity for the tested concentrations 
(25-500 μM). The concentration range was limited by the maximum concentration of 
the solvent (DMSO) that doesn’t affect cell viability (1%). In this case, it would be 
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interesting to extend the concentration range to detect toxic effects. For the RGS, a 
significant reduction of HaCaT viability was observed at the highest concentration 
tested (5000 μM) and was around 67% with MTT reduction assay.  
With regard to the results obtained from cytotoxicity assays of lipid nanoparticles a 
greater variability was observed. In some cases significant differences were observed 
between RSV-loaded and empty nanoparticles which were not consistent across the 
assays. We can generally assume that the toxicity observed is due to the particles 
rather than RSV. Indeed, the theoretical calculation of the concentration of RSV 
present in the highest concentration tested (0.1%), based on drug loading analysis 
previously performed, was 36.5 μM. But when free RSV was tested up 100 μM no 
significant evidence of cytotoxicity was detected, except for the NR assay. This 
suggests that the excipients used in the matrix of lipid nanoparticles or their physico-
chemical features (e.g. size and charge) could be responsible for the cell death. There 
is evidence that only the size of the nanoparticles is not sufficient to explain the 
cytotoxic effects [102]. It would be relevant to study the cytotoxicity of the ingredients 
alone to assess their contribution to the observed toxic effects. In the work by Ridolfi 
and co-workers, they showed that up to 0.5 mg/mL cetyl palmitate-based SLN caused 
a decrease in  HaCaT cell viability [127]. The type, amount and interaction of the 
surfactant with the lipid core on nanoparticles also affect  the performance of cells in 
culture [102]. Moreover there is evidence that the binding of surfactant to the 
nanoparticles surface decrease its availability to interact with cells and consequently 
decreases its toxicity [128]. So  it is essential testing of the unprocessed starting 
material present in the same quantities and ratios as in the final formulation to clarify if 
the observed toxicity effects are result of that particular combination of materials per se 
or of the nanoparticles in question [102]. 
On the other hand, the lipid nanoparticles may form aggregates in cell culture 
media or suffer changes to its structure, for example desorption of surfactants [102]. 
Therefore it is important to take into account the stability of the nanoparticles in cell 
medium [21, 102]. Studies performed in our laboratory with the same lipid 
nanoparticles, showed the zeta potential varied between 27 and 40 mV, which 
accounts for a good colloidal stability in aqueous dispersion [129].  
The majority of cell viability studies of SLN/NLC were performed by MTT assay 
[102]. The greater variability obtained in this study for lipid nanoparticles can also be 
explained by possible interactions between test reagents (e.g. MTT) and the 
nanoparticles, inducing false positives [21]. Furthermore, there is also evidence that 
SLN and NLC in the dispersion themselves absorb visible light [102]. To avoid the 
possibility of this lipid interaction with the assay, a washing step before adding the test 
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reagent was included in the protocol of cytotoxicity assays employed in this work, 
except for AlamarBlue® reduction assay. In this case, as is a water soluble dye, the 
blank measurement was included in this assay. But in blank for lipid nanoparticles 
contributed to optical density properties, which suggests that this cytotoxicity assay is 
not suitable for these nanoparticles. 
Regarding the polymeric microparticles the MTT reduction assay was the the only 
test used, and the aggregation and deposition of the microparticles on the surface of 
the cell monolayer led to a great variability of the results. 
Two of the compounds obtained by chemical synthesis, ACS and ASS were only 
tested with the MTT reduction assay, due to the reduced amount obtained in the 
synthesis process. ASS promoted a significant decrease in cell viability at the lowest 
concentration studied (100 μM). However this effect was not concentration-dependent, 
up to 1000 μM and cell viability was around 75%, which can be considered non-
cytotoxic [124], so this reduction in cell viability could be due to other effects such as an 
antiproliferative activity. Elucidation of the cytotoxicity should be further ascertained 
with other assays. ACS showed significant cytotoxicity only at the concentration of 500 
μM. 
1,2-DHX, another compound obtained by chemical synthesis, showed significant 
cytotoxicity at concentrations of 50 μM and higher. In the work by Silva and co-workers 
1,2-DHX was tested at several concentrations up to 50 μM with MTT reduction and 
Neutral Red uptake assays using Caco-2 cells. Silva et al. found no significant 
cytotoxicity within the tested concentration range [130]. 
In the case of the plant extract tested, no significant alterations of HaCaT cells 
viability were detected after incubation with concentrations lower than 250 μg/mL. In 
the work by Almeida and co-workers, this extract was tested with the MTT reduction 
assay, using HaCaT cells. Almeida et al. observed that the extract-induced cytotoxicity 
at concentrations equal to or higher than 50 μg/mL [111]. The dissimilarities found in 
both studies in terms of results could be explained by the different conditions used on 
the assay, such as different cell densities that restrains data comparison. 
As for the positive control used (10% DMSO), this proved to be a good cytotoxic 
compound, except for Trypan Blue exclusion assay. Indeed, microscopic observation of 
the cells incubated with DMSO in the trypan blue test, indicates that probably this 
reagent significantly compromised the cell membrane integrity, leading to cell burst and 
consequently unable the trypan blue dye to be up taken by dead cells. 
Regardless of the used assay, well defined protocols are needed to obtain 
meaningful results. In any cytotoxicity assays to be used, optimization must be carried 
out for every cell model [27]. Assays must be performed at a uniform temperature and 
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controlled pH to ensure reproducibility of all wells and across a plate. The optimum 
incubation time and cell density must be empirically determined [27]. All the tests used 
in this study for measure cytotoxicity of the different compounds were optimized. In 
particular, NR uptake and Trypan Blue exclusion assays showed more challenges for 
its proper implementation. NR assay was very dependent on temperature, forming 
crystals when there was a variation in temperature. Trypan blue is a manual test 
involving several cares, such as, collection of all cells (live and dead) from the well and 
the correct count of all cells is required. During assay optimization and development, 
microscopic observations are necessary for confirmation of cellular toxicity. Some of 
the observations include for example, cell detachment or presence of cell fragments 
[83]. This was particularly important for Trypan Blue exclusion assay, where it was 
found that 10% DMSO is not a good positive control. 
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6. CONCLUSIONS 
 
The aim of this work was to study the cytotoxicity of several ingredients with 
potential interest for topical application. Cytotoxicity assays are widely used in the 
preliminary investigation of the toxicity. From the study carried out in this Master 
dissertation we were able to determine the concentration range for each compound 
that can be used in future assays to confirm the potentialities of these raw materials for 
application on the skin. The results obtained are also relevant for other toxicological 
studies that are mandatory to meet regulatory requirements. 
 
The optimization of each cytotoxicity assay allowed the establishment of the most 
appropriate experimental conditions, considering the cell line used. The optimal cell 
density and incubation time with the test reagent were selected as follows: MTT 
reduction assay 1×104 cells/well and 2 h; AlamarBlue® reduction assay 2×104 cells/well 
and 4 h; NR uptake assay 2×104 cells/well and 4 h and Trypan Blue exclusion assay 
1×105 cells/well. The concentration of the NR solution used was 50 μg/mL. 
 
In the case of the RSV and its derivatives, they can be generally regarded as safe 
at concentrations up to 100 μM for RSV, 500 μM for RSV-Gli and 1000 μM for RGS.   
C. sativa leaf extract and 1,2-DHX can be safely used in future studies at 
concentrations up to 100 μg/mL and 50 μM, respectively. In turn, it would be necessary 
to complement the basic toxicity evaluation of ACS and ASS using more cytotoxicity 
studies. In particular, the absence of a concentration-dependent effect observed for 
ASS should be elucidated in future studies. 
 
The lipid nanoparticles prepared and tested in this work were not considered as 
promising topical ingredients due to the marked in vitro toxicity presented.  Our study 
also demonstrated that the nanoparticles present several challenges for toxicological 
testing. Improvement of the methodologies used should take into account the 
interaction between test reagents and nanoparticles and light dispersion or absorption 
effects that can interfere with the cytotoxicity assays. It would also be relevant to study 
the cytotoxicity of the ingredients alone to assess their contribution to the observed 
toxic effects. 
 
 Polymeric particles showed deposition on the surface of the cell monolayer and 
aggregation which led to a great variability of the results. Following these observations, 
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it would be more relevant to test the in vitro toxicity of these particles using for 
example, reconstructed human epidermis. 
 
When comparing the cytotoxicity assays used, some differences were noted, being 
the MTT reduction and NR uptake assays the most sensitive tests. These remarks 
further reinforce the importance of using different in vitro cytotoxicity tests, which rely 
on different mechanisms of cell death. 
  
Further toxicological tests should be carried out to meet regulatory requirements 
before considering the use of the tested compounds in cosmetic or pharmaceutical 
products. 
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